<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Europace</journal-id><journal-id journal-id-type="iso-abbrev">Europace</journal-id><journal-id journal-id-type="publisher-id">europace</journal-id><journal-title-group><journal-title>Europace</journal-title></journal-title-group><issn pub-type="ppub">1099-5129</issn><issn pub-type="epub">1532-2092</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28520924</article-id><article-id pub-id-type="pmc">5834147</article-id><article-id pub-id-type="doi">10.1093/europace/eux022</article-id><article-id pub-id-type="publisher-id">eux022</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject><subj-group subj-group-type="category-toc-heading"><subject>Atrial Fibrillation</subject></subj-group></subj-group></article-categories><title-group><article-title>Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Verdecchia</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="eux022-aff1">1</xref><xref ref-type="corresp" rid="eux022-cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Reboldi</surname><given-names>Gianpaolo</given-names></name><xref ref-type="aff" rid="eux022-aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Angeli</surname><given-names>Fabio</given-names></name><xref ref-type="aff" rid="eux022-aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mazzotta</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="eux022-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lip</surname><given-names>Gregory Y H</given-names></name><xref ref-type="aff" rid="eux022-aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Brueckmann</surname><given-names>Martina</given-names></name><xref ref-type="aff" rid="eux022-aff5">5</xref><xref ref-type="aff" rid="eux022-aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kleine</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="eux022-aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wallentin</surname><given-names>Lars</given-names></name><xref ref-type="aff" rid="eux022-aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ezekowitz</surname><given-names>Michael D</given-names></name><xref ref-type="aff" rid="eux022-aff8">8</xref><xref ref-type="aff" rid="eux022-aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Yusuf</surname><given-names>Salim</given-names></name><xref ref-type="aff" rid="eux022-aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Connolly</surname><given-names>Stuart J</given-names></name><xref ref-type="aff" rid="eux022-aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Di Pasquale</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="eux022-aff11">11</xref></contrib></contrib-group><aff id="eux022-aff1"><label>1</label>Department of Medicine, Hospital of Assisi, Assisi, Italy</aff><aff id="eux022-aff2"><label>2</label>Department of Medicine, University of Perugia, Perugia, Italy</aff><aff id="eux022-aff3"><label>3</label>Department of Cardiology and Cardiovascular Pathophysiology, Hospital S.M. della Misericordia, Perugia, Italy</aff><aff id="eux022-aff4"><label>4</label>University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK</aff><aff id="eux022-aff5"><label>5</label>Boehringer Ingelheim GmbH &amp; Co, Ingelheim am Rhein, Germany</aff><aff id="eux022-aff6"><label>6</label>Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany</aff><aff id="eux022-aff7"><label>7</label>Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden</aff><aff id="eux022-aff8"><label>8</label>Sidney Kimmel Medical College at Jefferson University, Philadelphia, PA, USA</aff><aff id="eux022-aff9"><label>9</label>Medical College and Lankenau Medical Center, Wynnewood, PA, USA</aff><aff id="eux022-aff10"><label>10</label>McMaster University, Hamilton, Ontario, Canada</aff><aff id="eux022-aff11"><label>11</label>Department of Cardiology, Maggiore Hospital, Bologna, Italy </aff><author-notes><corresp id="eux022-cor1"> Corresponding author. Tel: +39-3483318077; fax: +39-8139301. <italic>E-mail address</italic>: <email>verdec@tin.it</email>. </corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2018</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-05-17"><day>17</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>5</month><year>2017</year></pub-date><volume>20</volume><issue>2</issue><fpage>253</fpage><lpage>262</lpage><history><date date-type="received"><day>06</day><month>12</month><year>2016</year></date><date date-type="rev-recd"><day>21</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>1</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>© The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="eux022.pdf"></self-uri><abstract><title><offsets xml_i="6343" xml_f="6351" txt_i="11" txt_f="19">Abstract</offsets></title><sec id="s1"><title><offsets xml_i="6379" xml_f="6382" txt_i="20" txt_f="23">Aim</offsets></title><p><offsets xml_i="6393" xml_f="6570" txt_i="24" txt_f="201">We tested the hypothesis that left ventricular hypertrophy (LVH) interferes with the antithrombotic effects of dabigatran and warfarin in patients with atrial fibrillation (AF).</offsets></p></sec><sec id="s2"><title><offsets xml_i="6600" xml_f="6619" txt_i="203" txt_f="222">Methods and results</offsets></title><p><offsets xml_i="6630" xml_f="6640" txt_i="223" txt_f="233">This is a </offsets><italic><offsets xml_i="6648" xml_f="6656" txt_i="233" txt_f="241">post-hoc</offsets></italic><offsets xml_i="6665" xml_f="7587" txt_i="241" txt_f="1163"> analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) Study. We defined LVH by electrocardiography (ECG) and included patients with AF on the ECG tracing at entry. Hazard ratios (HR) for each dabigatran dose vs. warfarin were calculated in relation to LVH. LVH was present in 2353 (22.7%) out of 10 372 patients. In patients without LVH, the rates of primary outcome were 1.59%/year with warfarin, 1.60% with dabigatran 110 mg (HR vs. warfarin 1.01, 95% confidence interval (CI) 0.75–1.36) and 1.08% with dabigatran 150 mg (HR vs. warfarin 0.68, 95% CI 0.49–0.95). In patients with LVH, the rates of primary outcome were 3.21%/year with warfarin, 1.69% with dabigatran 110 mg (HR vs. warfarin 0.52, 95% CI 0.32–0.84) and 1.55% with 150 mg (HR vs. warfarin 0.48, 95% CI 0.29–0.78). The interaction between LVH status and dabigatran 110 mg vs. warfarin was significant for the primary outcome (</offsets><italic><offsets xml_i="7595" xml_f="7596" txt_i="1163" txt_f="1164">P</offsets></italic><offsets xml_i="7605" xml_f="7627" txt_i="1164" txt_f="1186"> = 0.021) and stroke (</offsets><italic><offsets xml_i="7635" xml_f="7636" txt_i="1186" txt_f="1187">P</offsets></italic><offsets xml_i="7645" xml_f="7856" txt_i="1187" txt_f="1398"> = 0.016). LVH was associated with a higher event rate with warfarin, not with dabigatran. In the warfarin group, the time in therapeutic range was significantly lower in the presence than in the absence of LVH.</offsets></p></sec><sec id="s3"><title><offsets xml_i="7886" xml_f="7897" txt_i="1400" txt_f="1411">Conclusions</offsets></title><p><offsets xml_i="7908" xml_f="8224" txt_i="1412" txt_f="1728">LVH was associated with a lower antithrombotic efficacy of warfarin, but not of dabigatran, in patients with AF. Consequently, the relative benefit of the lower dose of dabigatran compared to warfarin was enhanced in patients with LVH. The higher dose of dabigatran was superior to warfarin regardless of LVH status.</offsets></p></sec><sec id="s4"><title><offsets xml_i="8254" xml_f="8282" txt_i="1730" txt_f="1758">Clinical trial registration </offsets></title><p><offsets xml_i="8293" xml_f="8294" txt_i="1759" txt_f="1760">
</offsets><ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov"><offsets xml_i="8367" xml_f="8394" txt_i="1760" txt_f="1787">http:www.clinicaltrials.gov</offsets></ext-link><offsets xml_i="8405" xml_f="8438" txt_i="1787" txt_f="1820">. Unique identifier: NCT00262600.</offsets></p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Atrial fibrillation </kwd><kwd>Warfarin </kwd><kwd>Dabigatran </kwd><kwd>Stroke </kwd><kwd>Systemic embolism</kwd></kwd-group><counts><page-count count="10"></page-count></counts></article-meta></front><body><sec><title><offsets xml_i="8719" xml_f="8731" txt_i="1829" txt_f="1841">Introduction</offsets></title><p><offsets xml_i="8742" xml_f="8936" txt_i="1842" txt_f="2036">Left ventricular hypertrophy (LVH) diagnosed by traditional electrocardiography (ECG) portends a higher risk of stroke, death, and myocardial infarction in patients with atrial fibrillation (AF)</offsets><xref rid="eux022-B1" ref-type="bibr"><sup><offsets xml_i="8979" xml_f="8980" txt_i="2036" txt_f="2037">1</offsets></sup></xref><offsets xml_i="8993" xml_f="9040" txt_i="2037" txt_f="2084">. Patients with LVH have enhanced coagulability</offsets><xref rid="eux022-B2" ref-type="bibr"><sup><offsets xml_i="9083" xml_f="9084" txt_i="2084" txt_f="2085">2</offsets></sup></xref><sup><offsets xml_i="9102" xml_f="9103" txt_i="2085" txt_f="2086">,</offsets></sup><xref rid="eux022-B3" ref-type="bibr"><sup><offsets xml_i="9152" xml_f="9153" txt_i="2086" txt_f="2087">3</offsets></sup></xref><offsets xml_i="9166" xml_f="9184" txt_i="2087" txt_f="2105"> and inflammation.</offsets><xref rid="eux022-B4" ref-type="bibr"><sup><offsets xml_i="9227" xml_f="9228" txt_i="2105" txt_f="2106">4</offsets></sup></xref><sup><offsets xml_i="9246" xml_f="9247" txt_i="2106" txt_f="2107">,</offsets></sup><xref rid="eux022-B5" ref-type="bibr"><sup><offsets xml_i="9296" xml_f="9297" txt_i="2107" txt_f="2108">5</offsets></sup></xref><offsets xml_i="9310" xml_f="9398" txt_i="2108" txt_f="2196"> The higher risk of left atrial thrombosis in AF patients with LVH treated with warfarin</offsets><xref rid="eux022-B2" ref-type="bibr"><sup><offsets xml_i="9441" xml_f="9442" txt_i="2196" txt_f="2197">2</offsets></sup></xref><sup><offsets xml_i="9460" xml_f="9461" txt_i="2197" txt_f="2198">,</offsets></sup><xref rid="eux022-B6" ref-type="bibr"><sup><offsets xml_i="9510" xml_f="9511" txt_i="2198" txt_f="2199">6</offsets></sup></xref><sup><offsets xml_i="9529" xml_f="9530" txt_i="2199" txt_f="2200">,</offsets></sup><xref rid="eux022-B7" ref-type="bibr"><sup><offsets xml_i="9579" xml_f="9580" txt_i="2200" txt_f="2201">7</offsets></sup></xref><offsets xml_i="9593" xml_f="9760" txt_i="2201" txt_f="2368"> suggests that LVH might interfere with the efficacy of vitamin K antagonists. LVH has also been linked with a state of increased systemic inflammation in experimental</offsets><xref rid="eux022-B4" ref-type="bibr"><sup><offsets xml_i="9803" xml_f="9804" txt_i="2368" txt_f="2369">4</offsets></sup></xref><offsets xml_i="9817" xml_f="9830" txt_i="2369" txt_f="2382"> and clinical</offsets><xref rid="eux022-B5" ref-type="bibr"><sup><offsets xml_i="9873" xml_f="9874" txt_i="2382" txt_f="2383">5</offsets></sup></xref><offsets xml_i="9887" xml_f="10025" txt_i="2383" txt_f="2521"> studies. In this setting, there is evidence that thrombin may trigger inflammatory and fibrotic reactions beyond the coagulation cascade,</offsets><xref rid="eux022-B8" ref-type="bibr"><sup><offsets xml_i="10068" xml_f="10072" txt_i="2521" txt_f="2525">8–10</offsets></sup></xref><offsets xml_i="10085" xml_f="10172" txt_i="2525" txt_f="2612"> and that these reactions can be blunted by direct thrombin inhibition with dabigatran.</offsets><xref rid="eux022-B11" ref-type="bibr"><sup><offsets xml_i="10216" xml_f="10218" txt_i="2612" txt_f="2614">11</offsets></sup></xref><sup><offsets xml_i="10236" xml_f="10237" txt_i="2614" txt_f="2615">,</offsets></sup><xref rid="eux022-B12" ref-type="bibr"><sup><offsets xml_i="10287" xml_f="10289" txt_i="2615" txt_f="2617">12</offsets></sup></xref></p><p><offsets xml_i="10309" xml_f="10506" txt_i="2618" txt_f="2815">The experimental and clinical findings summarized above led us to hypothesize that LVH might interfere with the antithrombotic effects of dabigatran, as compared with warfarin, in patients with AF.</offsets></p><p><offsets xml_i="10513" xml_f="10557" txt_i="2816" txt_f="2860">To evaluate this hypothesis, we performed a </offsets><italic><offsets xml_i="10565" xml_f="10573" txt_i="2860" txt_f="2868">post-hoc</offsets></italic><offsets xml_i="10582" xml_f="10718" txt_i="2868" txt_f="3004"> subgroup analysis of AF patients with and without LVH from the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) Study</offsets><xref rid="eux022-B13" ref-type="bibr"><sup><offsets xml_i="10762" xml_f="10764" txt_i="3004" txt_f="3006">13</offsets></sup></xref><offsets xml_i="10777" xml_f="10812" txt_i="3006" txt_f="3041"> regarding major clinical outcomes.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="10853" xml_f="10860" txt_i="3043" txt_f="3050">Methods</offsets></title><p><offsets xml_i="10871" xml_f="11135" txt_i="3051" txt_f="3315">The RE-LY Study (NCT00262600) was a randomized non-inferiority trial of two doses of dabigatran, 110 mg bid and 150 mg bid, compared with warfarin for prevention of stroke or systemic embolism in patients with AF and at least one additional risk factor for stroke.</offsets><xref rid="eux022-B13" ref-type="bibr"><sup><offsets xml_i="11179" xml_f="11181" txt_i="3315" txt_f="3317">13</offsets></sup></xref><offsets xml_i="11194" xml_f="11236" txt_i="3317" txt_f="3359"> Details of the study have been published.</offsets><xref rid="eux022-B13" ref-type="bibr"><sup><offsets xml_i="11280" xml_f="11282" txt_i="3359" txt_f="3361">13</offsets></sup></xref><sup><offsets xml_i="11300" xml_f="11301" txt_i="3361" txt_f="3362">,</offsets></sup><xref rid="eux022-B14" ref-type="bibr"><sup><offsets xml_i="11351" xml_f="11353" txt_i="3362" txt_f="3364">14</offsets></sup></xref><offsets xml_i="11366" xml_f="11676" txt_i="3364" txt_f="3674"> The authors of this study had full access to the data and designed the statistical analysis plan. We included patients with the diagnosis of AF on the ECG carried out at entry. We excluded those with conditions potentially interfering with the ECG interpretation for LVH, as well as patients in sinus rhythm (</offsets><italic><offsets xml_i="11684" xml_f="11691" txt_i="3674" txt_f="3681">Figure </offsets></italic><xref ref-type="fig" rid="eux022-F1"><italic><offsets xml_i="11745" xml_f="11746" txt_i="3681" txt_f="3682">1</offsets></italic></xref><offsets xml_i="11762" xml_f="11852" txt_i="3682" txt_f="3772">) because the prognostic value of ECG LVH in patients in sinus rhythm is well established.</offsets></p><p><offsets xml_i="11859" xml_f="12220" txt_i="3773" txt_f="4134">All patients had a 25 mm/sec 12-lead ECG at entry and then annually up to the final follow-up visit or premature discontinuation of the study. An expert reader blinded to the patients’ features and randomized treatment examined the baseline ECG tracings of all patients. We categorized LVH by ECG using a binary (yes/no) variable by one or both of the following</offsets><xref rid="eux022-B15" ref-type="bibr"><sup><offsets xml_i="12264" xml_f="12266" txt_i="4134" txt_f="4136">15</offsets></sup></xref><offsets xml_i="12279" xml_f="12348" txt_i="4136" txt_f="4205">: (i) sum of the R wave in lead aVL and depth of the S wave in lead V</offsets><sub><offsets xml_i="12353" xml_f="12355" txt_i="4205" txt_f="4207">3 </offsets></sub><offsets xml_i="12361" xml_f="12365" txt_i="4207" txt_f="4208">&gt;</offsets><sub><offsets xml_i="12370" xml_f="12371" txt_i="4208" txt_f="4209"> </offsets></sub><offsets xml_i="12377" xml_f="12495" txt_i="4209" txt_f="4324">2.0 mV in women and &gt;2.4 mV in men and (ii) strain pattern in at least one of the following leads: I, II, aVL, or V</offsets><sub><offsets xml_i="12500" xml_f="12501" txt_i="4324" txt_f="4325">4</offsets></sub><offsets xml_i="12507" xml_f="12509" txt_i="4325" txt_f="4327">–V</offsets><sub><offsets xml_i="12514" xml_f="12515" txt_i="4327" txt_f="4328">6</offsets></sub><offsets xml_i="12521" xml_f="12711" txt_i="4328" txt_f="4518">. Strain pattern was considered present if there was ST-segment depression of at least 0.5 mm and inverted T wave in any of the above leads in the direction opposite the polarity of the QRS.</offsets></p><p><offsets xml_i="12718" xml_f="13024" txt_i="4519" txt_f="4825">The primary outcome was a composite of stroke and systemic embolism. Other efficacy outcomes were all-cause stroke, all-cause death and vascular death. Safety outcomes were any bleedings, major bleedings and intracranial bleedings. All the above outcomes have been associated with ECG LVH in prior studies.</offsets><xref rid="eux022-B16" ref-type="bibr"><sup><offsets xml_i="13068" xml_f="13070" txt_i="4825" txt_f="4827">16</offsets></sup></xref><sup><offsets xml_i="13088" xml_f="13089" txt_i="4827" txt_f="4828">,</offsets></sup><xref rid="eux022-B17" ref-type="bibr"><sup><offsets xml_i="13139" xml_f="13141" txt_i="4828" txt_f="4830">17</offsets></sup></xref><offsets xml_i="13154" xml_f="13215" txt_i="4830" txt_f="4891"> Criteria used for definitions of events have been published.</offsets><xref rid="eux022-B14" ref-type="bibr"><sup><offsets xml_i="13259" xml_f="13261" txt_i="4891" txt_f="4893">14</offsets></sup></xref><offsets xml_i="13274" xml_f="13404" txt_i="4893" txt_f="5023"> Deaths were adjudicated as being vascular or non-vascular, due to other specified causes such as cancer, or of unknown aetiology.</offsets></p><sec><title><offsets xml_i="13420" xml_f="13433" txt_i="5024" txt_f="5037">Data analysis</offsets></title><p><offsets xml_i="13444" xml_f="14695" txt_i="5038" txt_f="6289">We used SAS software, version 9.4 (SAS Institute, Cary, NC). We present continuous data as mean (±standard deviation) and categorical data as frequencies. We compared the characteristics of patients with and without LVH in the three randomized groups by chi-squared test and analysis of variance. We categorized LVH as present or absent. We restricted analysis to the first event in those patients who experienced multiple events and limited the outcome measures to the primary RE-LY outcome (composite of stroke or systemic embolism), any stroke, cardiovascular mortality, and all-cause mortality. We did not analyse systemic embolism alone because of the small number of events (10 with dabigatran 110 mg, 7 with dabigatran 150 mg, and 14 with warfarin). We used the Kaplan–Meier product-limit method to estimate the curves, and the log-rank test to compare the curves. We report the risk of events as a percentage per year, estimated by dividing the total number of patients with events by the total number of patient-years of follow-up for the randomized set. For analyses based on the safety set, the total number of years on treatment was used for the denominator. We used the Cox model to test the effect of prognostic factors on time to event.</offsets><xref rid="eux022-B18" ref-type="bibr"><sup><offsets xml_i="14739" xml_f="14741" txt_i="6289" txt_f="6291">18</offsets></sup></xref><offsets xml_i="14754" xml_f="14985" txt_i="6291" txt_f="6522"> Separate analyses, with estimates of hazard ratio (HR) and 95% confidence interval (CI), were done for each of the two dabigatran doses (110 mg bid and 150 mg bid) vs. warfarin. In a multivariable analysis, we adjusted for the CHA</offsets><sub><offsets xml_i="14990" xml_f="14991" txt_i="6522" txt_f="6523">2</offsets></sub><offsets xml_i="14997" xml_f="14999" txt_i="6523" txt_f="6525">DS</offsets><sub><offsets xml_i="15004" xml_f="15005" txt_i="6525" txt_f="6526">2</offsets></sub><offsets xml_i="15011" xml_f="15021" txt_i="6526" txt_f="6536">VASc score</offsets><xref rid="eux022-B19" ref-type="bibr"><sup><offsets xml_i="15065" xml_f="15067" txt_i="6536" txt_f="6538">19</offsets></sup></xref><offsets xml_i="15080" xml_f="15397" txt_i="6538" txt_f="6855"> (categorized as 0–1, 2, ≥ 3) and other covariables not included in the score. These were body mass index, valvular heart disease at entry, current smoking at entry, glomerular filtration rate, use of digoxin at entry, permanent AF at entry, randomized treatment, LVH, and LVH x treatment interaction. We used the CHA</offsets><sub><offsets xml_i="15402" xml_f="15403" txt_i="6855" txt_f="6856">2</offsets></sub><offsets xml_i="15409" xml_f="15411" txt_i="6856" txt_f="6858">DS</offsets><sub><offsets xml_i="15416" xml_f="15417" txt_i="6858" txt_f="6859">2</offsets></sub><offsets xml_i="15423" xml_f="15669" txt_i="6859" txt_f="7105">VASc score, in place of its seven components taken separately, because of its growing use in clinical practice and also to preserve model parsimony and prevent overfitting. We also made an additional analysis with the single components of the CHA</offsets><sub><offsets xml_i="15674" xml_f="15675" txt_i="7105" txt_f="7106">2</offsets></sub><offsets xml_i="15681" xml_f="15683" txt_i="7106" txt_f="7108">DS</offsets><sub><offsets xml_i="15688" xml_f="15689" txt_i="7108" txt_f="7109">2</offsets></sub><offsets xml_i="15695" xml_f="15988" txt_i="7109" txt_f="7402">VASc score, in addition to the covariables listed above. An exploratory analysis of the international normalized ratio (INR) and time in therapeutic range (TTR), defined by an INR between 2.0 and 3.0 in the warfarin group, was undertaken on the basis of all available individual observations. </offsets><italic><offsets xml_i="15996" xml_f="15997" txt_i="7402" txt_f="7403">P</offsets></italic><offsets xml_i="16006" xml_f="16066" txt_i="7403" txt_f="7460">-values &lt; 0.05 were considered statistically significant.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="16113" xml_f="16120" txt_i="7463" txt_f="7470">Results</offsets></title><sec><title><offsets xml_i="16140" xml_f="16167" txt_i="7471" txt_f="7498">Characteristics of patients</offsets></title><p><offsets xml_i="16178" xml_f="16179" txt_i="7499" txt_f="7500">
</offsets><italic><offsets xml_i="16187" xml_f="16194" txt_i="7500" txt_f="7507">Figure </offsets></italic><offsets xml_i="16203" xml_f="16204" txt_i="7507" txt_f="7508">
</offsets><xref ref-type="fig" rid="eux022-F1"><offsets xml_i="16241" xml_f="16242" txt_i="7508" txt_f="7509">
</offsets><italic><offsets xml_i="16250" xml_f="16251" txt_i="7509" txt_f="7510">1</offsets></italic><offsets xml_i="16260" xml_f="16261" txt_i="7510" txt_f="7511">
</offsets></xref><offsets xml_i="16268" xml_f="16572" txt_i="7511" txt_f="7815"> shows the flow diagram of the study. Among 13 047 patients with AF or atrial flutter at entry as resulting from the clinical record form (CRF), and subjected to central ECG reading, 2675 patients were excluded due to the ECG being unsuitable for LVH analysis. The reasons of unsuitability are listed in </offsets><italic><offsets xml_i="16580" xml_f="16587" txt_i="7815" txt_f="7822">Figure </offsets></italic><xref ref-type="fig" rid="eux022-F1"><italic><offsets xml_i="16641" xml_f="16642" txt_i="7822" txt_f="7823">1</offsets></italic></xref><offsets xml_i="16658" xml_f="16725" txt_i="7823" txt_f="7890">. These patients showed, when compared to those with suitable ECG (</offsets><italic><offsets xml_i="16733" xml_f="16734" txt_i="7890" txt_f="7891">N</offsets></italic><offsets xml_i="16743" xml_f="16773" txt_i="7891" txt_f="7921"> = 10 372), a similar mean CHA</offsets><sub><offsets xml_i="16778" xml_f="16779" txt_i="7921" txt_f="7922">2</offsets></sub><offsets xml_i="16785" xml_f="16787" txt_i="7922" txt_f="7924">DS</offsets><sub><offsets xml_i="16792" xml_f="16793" txt_i="7924" txt_f="7925">2</offsets></sub><offsets xml_i="16799" xml_f="17002" txt_i="7925" txt_f="8128">VASc score (3.6 vs. 3.6) and a comparable history of diabetes (23.5% vs. 23.2%) and hypertension (79.8% vs. 78.2%). Age was marginally higher in the former than in the latter group (71.8 vs. 71.2 years; </offsets><italic><offsets xml_i="17010" xml_f="17011" txt_i="8128" txt_f="8129">P</offsets></italic><offsets xml_i="17020" xml_f="17033" txt_i="8129" txt_f="8139"> &lt; 0.01).
</offsets></p><fig id="eux022-F1" orientation="portrait" position="float"><label><offsets xml_i="17104" xml_f="17112" txt_i="8140" txt_f="8148">Figure 1</offsets></label><caption><p><offsets xml_i="17132" xml_f="17284" txt_i="8148" txt_f="8300">Flow diagram of the study. ECG, electrocardiography; LBBB, left bundle branch block; LVH, left ventricular hypertrophy; RBBB, right bundle branch block.</offsets></p></caption><graphic xlink:href="eux022f1"></graphic></fig><p><offsets xml_i="17348" xml_f="17349" txt_i="8301" txt_f="8302">
</offsets><italic><offsets xml_i="17357" xml_f="17363" txt_i="8302" txt_f="8308">Table </offsets></italic><offsets xml_i="17372" xml_f="17373" txt_i="8308" txt_f="8309">
</offsets><xref ref-type="table" rid="eux022-T1"><offsets xml_i="17412" xml_f="17413" txt_i="8309" txt_f="8310">
</offsets><italic><offsets xml_i="17421" xml_f="17422" txt_i="8310" txt_f="8311">1</offsets></italic><offsets xml_i="17431" xml_f="17432" txt_i="8311" txt_f="8312">
</offsets></xref><offsets xml_i="17439" xml_f="17868" txt_i="8312" txt_f="8741"> shows the main characteristics of patients. Prevalence of LVH was 22.7% (22.7% in the dabigatran 110 mg group, 22.9% in the dabigatran 150 mg group and 22.5% in the warfarin group). Patients with LVH showed, compared to those without LVH, a more frequent history of hypertension, diabetes, coronary heart disease, and heart failure, a lower estimated glomerular filtration rate and a higher systolic blood pressure (BP). The CHA</offsets><sub><offsets xml_i="17873" xml_f="17874" txt_i="8741" txt_f="8742">2</offsets></sub><offsets xml_i="17880" xml_f="17882" txt_i="8742" txt_f="8744">DS</offsets><sub><offsets xml_i="17887" xml_f="17888" txt_i="8744" txt_f="8745">2</offsets></sub><offsets xml_i="17894" xml_f="17962" txt_i="8745" txt_f="8813">VASc score was shifted towards higher values in the group with LVH.
</offsets><table-wrap id="eux022-T1" orientation="portrait" position="float"><label><offsets xml_i="18036" xml_f="18043" txt_i="8813" txt_f="8820">Table 1</offsets></label><caption><p><offsets xml_i="18063" xml_f="18109" txt_i="8820" txt_f="8866">Main features of the population—randomized set</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"></th><th rowspan="1" colspan="1"><offsets xml_i="18232" xml_f="18244" txt_i="8867" txt_f="8879">All patients</offsets></th><th colspan="2" rowspan="1"><offsets xml_i="18277" xml_f="18298" txt_i="8879" txt_f="8900">Dabigatran 110 mg bid</offsets><hr></hr></th><th colspan="2" rowspan="1"><offsets xml_i="18340" xml_f="18361" txt_i="8900" txt_f="8921">Dabigatran 150 mg bid</offsets><hr></hr></th><th colspan="2" rowspan="1"><offsets xml_i="18403" xml_f="18411" txt_i="8921" txt_f="8929">Warfarin</offsets><hr></hr></th><th rowspan="2" colspan="1"><italic><offsets xml_i="18461" xml_f="18462" txt_i="8929" txt_f="8930">P</offsets></italic><offsets xml_i="18471" xml_f="18477" txt_i="8930" txt_f="8936">-value</offsets><xref ref-type="table-fn" rid="tblfn5"><offsets xml_i="18516" xml_f="18517" txt_i="8936" txt_f="8937">*</offsets></xref></th></tr><tr><th rowspan="1" colspan="1"><italic><offsets xml_i="18574" xml_f="18575" txt_i="8937" txt_f="8938">N</offsets></italic><offsets xml_i="18584" xml_f="18593" txt_i="8938" txt_f="8947"> = 10 372</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="18626" xml_f="18632" txt_i="8947" txt_f="8953">LVH − </offsets><italic><offsets xml_i="18640" xml_f="18641" txt_i="8953" txt_f="8954">N</offsets></italic><offsets xml_i="18650" xml_f="18657" txt_i="8954" txt_f="8961"> = 2701</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="18690" xml_f="18696" txt_i="8961" txt_f="8967">LVH + </offsets><italic><offsets xml_i="18704" xml_f="18705" txt_i="8967" txt_f="8968">N</offsets></italic><offsets xml_i="18714" xml_f="18720" txt_i="8968" txt_f="8974"> = 791</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="18753" xml_f="18759" txt_i="8974" txt_f="8980">LVH − </offsets><italic><offsets xml_i="18767" xml_f="18768" txt_i="8980" txt_f="8981">N</offsets></italic><offsets xml_i="18777" xml_f="18784" txt_i="8981" txt_f="8988"> = 2666</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="18817" xml_f="18823" txt_i="8988" txt_f="8994">LVH + </offsets><italic><offsets xml_i="18831" xml_f="18832" txt_i="8994" txt_f="8995">N</offsets></italic><offsets xml_i="18841" xml_f="18847" txt_i="8995" txt_f="9001"> = 791</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="18880" xml_f="18886" txt_i="9001" txt_f="9007">LVH – </offsets><italic><offsets xml_i="18894" xml_f="18895" txt_i="9007" txt_f="9008">N</offsets></italic><offsets xml_i="18904" xml_f="18911" txt_i="9008" txt_f="9015"> = 2652</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="18944" xml_f="18950" txt_i="9015" txt_f="9021">LVH + </offsets><italic><offsets xml_i="18958" xml_f="18959" txt_i="9021" txt_f="9022">N</offsets></italic><offsets xml_i="18968" xml_f="18974" txt_i="9022" txt_f="9028"> = 771</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="19031" xml_f="19042" txt_i="9028" txt_f="9039">Age (years)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19075" xml_f="19083" txt_i="9040" txt_f="9048">71.2 (9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19116" xml_f="19124" txt_i="9049" txt_f="9057">71.1 (9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19157" xml_f="19165" txt_i="9058" txt_f="9066">71.4 (9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19198" xml_f="19206" txt_i="9067" txt_f="9075">71.3 (9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19239" xml_f="19248" txt_i="9076" txt_f="9085">70.7 (10)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19281" xml_f="19289" txt_i="9086" txt_f="9094">71.5 (8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19322" xml_f="19330" txt_i="9095" txt_f="9103">71.1 (9)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="19385" xml_f="19391" txt_i="9104" txt_f="9110">0.2368</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="19433" xml_f="19440" txt_i="9111" txt_f="9118">Men (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19473" xml_f="19477" txt_i="9119" txt_f="9123">65.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19510" xml_f="19514" txt_i="9124" txt_f="9128">67.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19547" xml_f="19551" txt_i="9129" txt_f="9133">61.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19584" xml_f="19588" txt_i="9134" txt_f="9138">66.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19621" xml_f="19625" txt_i="9139" txt_f="9143">58.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19658" xml_f="19662" txt_i="9144" txt_f="9148">66.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19695" xml_f="19699" txt_i="9149" txt_f="9153">60.1</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="19754" xml_f="19764" txt_i="9154" txt_f="9161">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="19806" xml_f="19822" txt_i="9162" txt_f="9178">Body weight (kg)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19855" xml_f="19862" txt_i="9179" txt_f="9186">83 (20)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19895" xml_f="19902" txt_i="9187" txt_f="9194">85 (21)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19935" xml_f="19942" txt_i="9195" txt_f="9202">80 (19)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19975" xml_f="19982" txt_i="9203" txt_f="9210">84 (20)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20015" xml_f="20022" txt_i="9211" txt_f="9218">79 (20)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20055" xml_f="20062" txt_i="9219" txt_f="9226">84 (20)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20095" xml_f="20102" txt_i="9227" txt_f="9234">79 (19)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="20157" xml_f="20167" txt_i="9235" txt_f="9242">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="20209" xml_f="20220" txt_i="9243" txt_f="9254">BMI (kg/(m)</offsets><sup><offsets xml_i="20225" xml_f="20226" txt_i="9254" txt_f="9255">2</offsets></sup><offsets xml_i="20232" xml_f="20233" txt_i="9255" txt_f="9256">)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20266" xml_f="20274" txt_i="9257" txt_f="9265">28.9 (6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20307" xml_f="20315" txt_i="9266" txt_f="9274">29.2 (6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20348" xml_f="20356" txt_i="9275" txt_f="9283">28.1 (6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20389" xml_f="20397" txt_i="9284" txt_f="9292">29.1 (6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20430" xml_f="20438" txt_i="9293" txt_f="9301">28.0 (6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20471" xml_f="20479" txt_i="9302" txt_f="9310">29.1 (6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20512" xml_f="20520" txt_i="9311" txt_f="9319">28.2 (6)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="20575" xml_f="20585" txt_i="9320" txt_f="9327">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="20627" xml_f="20640" txt_i="9328" txt_f="9341">CrCl (mL/min)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20673" xml_f="20682" txt_i="9342" txt_f="9351">73.6 (28)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20715" xml_f="20724" txt_i="9352" txt_f="9361">75.4 (29)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20757" xml_f="20766" txt_i="9362" txt_f="9371">69.4 (26)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20799" xml_f="20808" txt_i="9372" txt_f="9381">74.8 (28)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20841" xml_f="20850" txt_i="9382" txt_f="9391">69.0 (26)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20883" xml_f="20892" txt_i="9392" txt_f="9401">74.9 (27)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="20925" xml_f="20934" txt_i="9402" txt_f="9411">67.8 (27)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="20989" xml_f="20999" txt_i="9412" txt_f="9419">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="21041" xml_f="21054" txt_i="9420" txt_f="9433">Ethnicity (%)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="21340" xml_f="21346" txt_i="9441" txt_f="9447">0.0003</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="21388" xml_f="21398" txt_i="9448" txt_f="9458"> Caucasian</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21431" xml_f="21435" txt_i="9459" txt_f="9463">80.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21468" xml_f="21472" txt_i="9464" txt_f="9468">82.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21505" xml_f="21509" txt_i="9469" txt_f="9473">78.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21542" xml_f="21546" txt_i="9474" txt_f="9478">81.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21579" xml_f="21583" txt_i="9479" txt_f="9483">77.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21616" xml_f="21620" txt_i="9484" txt_f="9488">80.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21653" xml_f="21657" txt_i="9489" txt_f="9493">78.5</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="21732" xml_f="21738" txt_i="9495" txt_f="9501"> Asian</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21771" xml_f="21775" txt_i="9502" txt_f="9506">18.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21808" xml_f="21812" txt_i="9507" txt_f="9511">16.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21845" xml_f="21849" txt_i="9512" txt_f="9516">21.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21882" xml_f="21886" txt_i="9517" txt_f="9521">18.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21919" xml_f="21923" txt_i="9522" txt_f="9526">21.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21956" xml_f="21960" txt_i="9527" txt_f="9531">18.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="21993" xml_f="21997" txt_i="9532" txt_f="9536">19.8</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="22072" xml_f="22078" txt_i="9538" txt_f="9544"> Black</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22111" xml_f="22114" txt_i="9545" txt_f="9548">1.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22147" xml_f="22150" txt_i="9549" txt_f="9552">0.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22183" xml_f="22186" txt_i="9553" txt_f="9556">0.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22219" xml_f="22222" txt_i="9557" txt_f="9560">0.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22255" xml_f="22258" txt_i="9561" txt_f="9564">1.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22291" xml_f="22294" txt_i="9565" txt_f="9568">1.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22327" xml_f="22330" txt_i="9569" txt_f="9572">1.7</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="22405" xml_f="22436" txt_i="9574" txt_f="9605">Type of atrial fibrillation (%)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="22722" xml_f="22728" txt_i="9613" txt_f="9619">0.0239</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="22770" xml_f="22781" txt_i="9620" txt_f="9631"> Paroxysmal</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22814" xml_f="22818" txt_i="9632" txt_f="9636">15.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22851" xml_f="22855" txt_i="9637" txt_f="9641">16.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22888" xml_f="22892" txt_i="9642" txt_f="9646">14.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22925" xml_f="22929" txt_i="9647" txt_f="9651">15.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22962" xml_f="22966" txt_i="9652" txt_f="9656">15.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22999" xml_f="23003" txt_i="9657" txt_f="9661">16.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23036" xml_f="23040" txt_i="9662" txt_f="9666">14.8</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23115" xml_f="23126" txt_i="9668" txt_f="9679"> Persistent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23159" xml_f="23163" txt_i="9680" txt_f="9684">37.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23196" xml_f="23200" txt_i="9685" txt_f="9689">38.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23233" xml_f="23237" txt_i="9690" txt_f="9694">36.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23270" xml_f="23274" txt_i="9695" txt_f="9699">37.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23307" xml_f="23311" txt_i="9700" txt_f="9704">34.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23344" xml_f="23348" txt_i="9705" txt_f="9709">39.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23381" xml_f="23385" txt_i="9710" txt_f="9714">37.2</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23460" xml_f="23470" txt_i="9716" txt_f="9726"> Permanent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23503" xml_f="23507" txt_i="9727" txt_f="9731">46.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23540" xml_f="23544" txt_i="9732" txt_f="9736">45.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23577" xml_f="23581" txt_i="9737" txt_f="9741">48.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23614" xml_f="23618" txt_i="9742" txt_f="9746">47.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23651" xml_f="23655" txt_i="9747" txt_f="9751">49.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23688" xml_f="23692" txt_i="9752" txt_f="9756">44.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23725" xml_f="23729" txt_i="9757" txt_f="9761">48.0</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23804" xml_f="23823" txt_i="9763" txt_f="9782">Medical history (%)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24129" xml_f="24142" txt_i="9791" txt_f="9804"> Hypertension</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24175" xml_f="24179" txt_i="9805" txt_f="9809">78.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24212" xml_f="24216" txt_i="9810" txt_f="9814">76.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24249" xml_f="24253" txt_i="9815" txt_f="9819">80.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24286" xml_f="24290" txt_i="9820" txt_f="9824">79.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24323" xml_f="24327" txt_i="9825" txt_f="9829">78.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24360" xml_f="24364" txt_i="9830" txt_f="9834">77.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24397" xml_f="24401" txt_i="9835" txt_f="9839">80.2</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24456" xml_f="24462" txt_i="9840" txt_f="9846">0.0525</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24504" xml_f="24522" txt_i="9847" txt_f="9865"> Diabetes mellitus</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24555" xml_f="24559" txt_i="9866" txt_f="9870">23.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24592" xml_f="24596" txt_i="9871" txt_f="9875">21.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24629" xml_f="24633" txt_i="9876" txt_f="9880">26.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24666" xml_f="24670" txt_i="9881" txt_f="9885">22.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24703" xml_f="24707" txt_i="9886" txt_f="9890">26.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24740" xml_f="24744" txt_i="9891" txt_f="9895">21.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24777" xml_f="24781" txt_i="9896" txt_f="9900">28.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24836" xml_f="24846" txt_i="9901" txt_f="9908">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24888" xml_f="24912" txt_i="9909" txt_f="9933"> Coronary artery disease</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24945" xml_f="24949" txt_i="9934" txt_f="9938">25.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24982" xml_f="24986" txt_i="9939" txt_f="9943">24.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25019" xml_f="25023" txt_i="9944" txt_f="9948">29.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25056" xml_f="25060" txt_i="9949" txt_f="9953">24.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25093" xml_f="25097" txt_i="9954" txt_f="9958">28.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25130" xml_f="25134" txt_i="9959" txt_f="9963">24.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25167" xml_f="25171" txt_i="9964" txt_f="9968">30.1</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25226" xml_f="25236" txt_i="9969" txt_f="9976">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25278" xml_f="25292" txt_i="9977" txt_f="9991"> Heart failure</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25325" xml_f="25329" txt_i="9992" txt_f="9996">33.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25362" xml_f="25366" txt_i="9997" txt_f="10001">29.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25399" xml_f="25403" txt_i="10002" txt_f="10006">45.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25436" xml_f="25440" txt_i="10007" txt_f="10011">29.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25473" xml_f="25477" txt_i="10012" txt_f="10016">47.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25510" xml_f="25514" txt_i="10017" txt_f="10021">28.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25547" xml_f="25551" txt_i="10022" txt_f="10026">46.7</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25606" xml_f="25616" txt_i="10027" txt_f="10034">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25658" xml_f="25665" txt_i="10035" txt_f="10042"> Stroke</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25698" xml_f="25702" txt_i="10043" txt_f="10047">13.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25735" xml_f="25739" txt_i="10048" txt_f="10052">13.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25772" xml_f="25776" txt_i="10053" txt_f="10057">14.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25809" xml_f="25813" txt_i="10058" txt_f="10062">13.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25846" xml_f="25850" txt_i="10063" txt_f="10067">12.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25883" xml_f="25887" txt_i="10068" txt_f="10072">12.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25920" xml_f="25924" txt_i="10073" txt_f="10077">15.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25979" xml_f="25985" txt_i="10078" txt_f="10084">0.2236</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="26027" xml_f="26044" txt_i="10085" txt_f="10102"> Non CNS embolism</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26077" xml_f="26080" txt_i="10103" txt_f="10106">2.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26113" xml_f="26116" txt_i="10107" txt_f="10110">2.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26149" xml_f="26152" txt_i="10111" txt_f="10114">2.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26185" xml_f="26188" txt_i="10115" txt_f="10118">2.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26221" xml_f="26224" txt_i="10119" txt_f="10122">2.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26257" xml_f="26260" txt_i="10123" txt_f="10126">2.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26293" xml_f="26296" txt_i="10127" txt_f="10130">1.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26351" xml_f="26357" txt_i="10131" txt_f="10137">0.7157</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="26399" xml_f="26414" txt_i="10138" txt_f="10153">Current smoking</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26447" xml_f="26450" txt_i="10154" txt_f="10157">7.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26483" xml_f="26486" txt_i="10158" txt_f="10161">7.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26519" xml_f="26522" txt_i="10162" txt_f="10165">8.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26555" xml_f="26558" txt_i="10166" txt_f="10169">7.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26591" xml_f="26594" txt_i="10170" txt_f="10173">7.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26627" xml_f="26630" txt_i="10174" txt_f="10177">7.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26663" xml_f="26666" txt_i="10178" txt_f="10181">8.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26721" xml_f="26727" txt_i="10182" txt_f="10188">0.5355</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="26769" xml_f="26787" txt_i="10189" txt_f="10207">Systolic BP (mmHg)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26820" xml_f="26828" txt_i="10208" txt_f="10216">130 (17)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26861" xml_f="26869" txt_i="10217" txt_f="10225">130 (17)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26902" xml_f="26910" txt_i="10226" txt_f="10234">133 (18)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26943" xml_f="26951" txt_i="10235" txt_f="10243">129 (16)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26984" xml_f="26992" txt_i="10244" txt_f="10252">132 (18)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27025" xml_f="27033" txt_i="10253" txt_f="10261">130 (17)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27066" xml_f="27074" txt_i="10262" txt_f="10270">132 (18)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27129" xml_f="27139" txt_i="10271" txt_f="10278">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="27181" xml_f="27200" txt_i="10279" txt_f="10298">Diastolic BP (mmHg)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27233" xml_f="27240" txt_i="10299" txt_f="10306">78 (11)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27273" xml_f="27280" txt_i="10307" txt_f="10314">78 (11)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27313" xml_f="27320" txt_i="10315" txt_f="10322">78 (11)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27353" xml_f="27360" txt_i="10323" txt_f="10330">78 (11)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27393" xml_f="27400" txt_i="10331" txt_f="10338">78 (11)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27433" xml_f="27440" txt_i="10339" txt_f="10346">78 (10)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27473" xml_f="27480" txt_i="10347" txt_f="10354">78 (11)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27535" xml_f="27541" txt_i="10355" txt_f="10361">0.4170</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="27583" xml_f="27605" txt_i="10362" txt_f="10384">Heart Rate (beats/min)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27638" xml_f="27645" txt_i="10385" txt_f="10392">77 (15)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27678" xml_f="27685" txt_i="10393" txt_f="10400">77 (15)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27718" xml_f="27725" txt_i="10401" txt_f="10408">77 (15)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27758" xml_f="27765" txt_i="10409" txt_f="10416">77 (15)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27798" xml_f="27805" txt_i="10417" txt_f="10424">77 (15)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27838" xml_f="27845" txt_i="10425" txt_f="10432">77 (15)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27878" xml_f="27885" txt_i="10433" txt_f="10440">76 (15)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27940" xml_f="27946" txt_i="10441" txt_f="10447">0.3384</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="27988" xml_f="28012" txt_i="10448" txt_f="10472">Waist circumference (cm)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28045" xml_f="28055" txt_i="10473" txt_f="10483">101.1 (21)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28088" xml_f="28098" txt_i="10484" txt_f="10494">102.3 (24)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28131" xml_f="28140" txt_i="10495" txt_f="10504">98.9 (15)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28173" xml_f="28183" txt_i="10505" txt_f="10515">102.0 (26)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28216" xml_f="28225" txt_i="10516" txt_f="10525">97.9 (15)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28258" xml_f="28268" txt_i="10526" txt_f="10536">101.4 (17)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28301" xml_f="28310" txt_i="10537" txt_f="10546">98.4 (16)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28365" xml_f="28375" txt_i="10547" txt_f="10554">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28417" xml_f="28444" txt_i="10555" txt_f="10582">Medication use at entry (%)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28750" xml_f="28764" txt_i="10591" txt_f="10605"> Antiplatelets</offsets><xref ref-type="table-fn" rid="tblfn3"><sup><offsets xml_i="28808" xml_f="28809" txt_i="10605" txt_f="10606">a</offsets></sup></xref></td><td rowspan="1" colspan="1"><offsets xml_i="28855" xml_f="28859" txt_i="10607" txt_f="10611">38.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28892" xml_f="28896" txt_i="10612" txt_f="10616">37.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28929" xml_f="28933" txt_i="10617" txt_f="10621">43.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28966" xml_f="28970" txt_i="10622" txt_f="10626">36.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29003" xml_f="29007" txt_i="10627" txt_f="10631">41.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29040" xml_f="29044" txt_i="10632" txt_f="10636">39.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29077" xml_f="29081" txt_i="10637" txt_f="10641">41.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="29136" xml_f="29142" txt_i="10642" txt_f="10648">0.0003</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29184" xml_f="29192" txt_i="10649" txt_f="10657"> Digoxin</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29225" xml_f="29229" txt_i="10658" txt_f="10662">34.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29262" xml_f="29266" txt_i="10663" txt_f="10667">30.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29299" xml_f="29303" txt_i="10668" txt_f="10672">51.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29336" xml_f="29340" txt_i="10673" txt_f="10677">29.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29373" xml_f="29377" txt_i="10678" txt_f="10682">48.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29410" xml_f="29414" txt_i="10683" txt_f="10687">29.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29447" xml_f="29451" txt_i="10688" txt_f="10692">51.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="29506" xml_f="29516" txt_i="10693" txt_f="10700">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29558" xml_f="29572" txt_i="10701" txt_f="10715"> Beta-blockers</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29605" xml_f="29609" txt_i="10716" txt_f="10720">62.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29642" xml_f="29646" txt_i="10721" txt_f="10725">62.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29679" xml_f="29683" txt_i="10726" txt_f="10730">60.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29716" xml_f="29720" txt_i="10731" txt_f="10735">62.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29753" xml_f="29757" txt_i="10736" txt_f="10740">65.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29790" xml_f="29794" txt_i="10741" txt_f="10745">61.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29827" xml_f="29831" txt_i="10746" txt_f="10750">61.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="29886" xml_f="29892" txt_i="10751" txt_f="10757">0.7491</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29934" xml_f="29957" txt_i="10758" txt_f="10781"> ARBs or ACE inhibitors</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29990" xml_f="29994" txt_i="10782" txt_f="10786">65.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30027" xml_f="30031" txt_i="10787" txt_f="10791">63.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30064" xml_f="30068" txt_i="10792" txt_f="10796">74.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30101" xml_f="30105" txt_i="10797" txt_f="10801">65.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30138" xml_f="30142" txt_i="10802" txt_f="10806">70.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30175" xml_f="30179" txt_i="10807" txt_f="10811">62.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30212" xml_f="30216" txt_i="10812" txt_f="10816">71.2</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="30271" xml_f="30281" txt_i="10817" txt_f="10824">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="30323" xml_f="30334" txt_i="10825" txt_f="10836"> Amiodarone</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30367" xml_f="30370" txt_i="10837" txt_f="10840">7.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30403" xml_f="30406" txt_i="10841" txt_f="10844">6.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30439" xml_f="30442" txt_i="10845" txt_f="10848">9.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30475" xml_f="30478" txt_i="10849" txt_f="10852">6.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30511" xml_f="30515" txt_i="10853" txt_f="10857">10.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30548" xml_f="30551" txt_i="10858" txt_f="10861">6.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30584" xml_f="30587" txt_i="10862" txt_f="10865">9.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="30642" xml_f="30652" txt_i="10866" txt_f="10873">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="30694" xml_f="30717" txt_i="10874" txt_f="10897"> Proton-pump inhibitors</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30750" xml_f="30754" txt_i="10898" txt_f="10902">12.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30787" xml_f="30791" txt_i="10903" txt_f="10907">13.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30824" xml_f="30828" txt_i="10908" txt_f="10912">13.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30861" xml_f="30865" txt_i="10913" txt_f="10917">12.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30898" xml_f="30902" txt_i="10918" txt_f="10922">13.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30935" xml_f="30939" txt_i="10923" txt_f="10927">12.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30972" xml_f="30976" txt_i="10928" txt_f="10932">13.2</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="31031" xml_f="31037" txt_i="10933" txt_f="10939">0.3953</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31079" xml_f="31087" txt_i="10940" txt_f="10948"> Statins</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31120" xml_f="31124" txt_i="10949" txt_f="10953">41.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31157" xml_f="31161" txt_i="10954" txt_f="10958">42.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31194" xml_f="31198" txt_i="10959" txt_f="10963">41.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31231" xml_f="31235" txt_i="10964" txt_f="10968">41.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31268" xml_f="31272" txt_i="10969" txt_f="10973">39.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31305" xml_f="31309" txt_i="10974" txt_f="10978">42.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31342" xml_f="31346" txt_i="10979" txt_f="10983">38.9</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="31401" xml_f="31407" txt_i="10984" txt_f="10990">0.0726</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31449" xml_f="31471" txt_i="10991" txt_f="11013"> Long term VKA Therapy</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31504" xml_f="31508" txt_i="11014" txt_f="11018">70.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31541" xml_f="31545" txt_i="11019" txt_f="11023">71.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31578" xml_f="31582" txt_i="11024" txt_f="11028">66.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31615" xml_f="31619" txt_i="11029" txt_f="11033">71.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31652" xml_f="31656" txt_i="11034" txt_f="11038">66.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31689" xml_f="31693" txt_i="11039" txt_f="11043">70.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31726" xml_f="31730" txt_i="11044" txt_f="11048">66.3</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="31785" xml_f="31795" txt_i="11049" txt_f="11056">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31837" xml_f="31840" txt_i="11057" txt_f="11060">CHA</offsets><sub><offsets xml_i="31845" xml_f="31846" txt_i="11060" txt_f="11061">2</offsets></sub><offsets xml_i="31852" xml_f="31854" txt_i="11061" txt_f="11063">DS</offsets><sub></sub><offsets xml_i="31865" xml_f="31879" txt_i="11063" txt_f="11077">VASc score (%)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="32165" xml_f="32175" txt_i="11085" txt_f="11092">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32217" xml_f="32221" txt_i="11093" txt_f="11097"> 0–1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32254" xml_f="32257" txt_i="11098" txt_f="11101">3.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32290" xml_f="32293" txt_i="11102" txt_f="11105">4.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32326" xml_f="32329" txt_i="11106" txt_f="11109">3.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32362" xml_f="32365" txt_i="11110" txt_f="11113">3.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32398" xml_f="32401" txt_i="11114" txt_f="11117">3.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32434" xml_f="32437" txt_i="11118" txt_f="11121">4.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32470" xml_f="32473" txt_i="11122" txt_f="11125">2.3</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32548" xml_f="32550" txt_i="11127" txt_f="11129"> 2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32583" xml_f="32587" txt_i="11130" txt_f="11134">20.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32620" xml_f="32624" txt_i="11135" txt_f="11139">21.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32657" xml_f="32661" txt_i="11140" txt_f="11144">14.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32694" xml_f="32698" txt_i="11145" txt_f="11149">22.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32731" xml_f="32735" txt_i="11150" txt_f="11154">17.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32768" xml_f="32772" txt_i="11155" txt_f="11159">20.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32805" xml_f="32809" txt_i="11160" txt_f="11164">16.3</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32884" xml_f="32888" txt_i="11166" txt_f="11170"> ≥ 3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32921" xml_f="32925" txt_i="11171" txt_f="11175">76.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32958" xml_f="32962" txt_i="11176" txt_f="11180">74.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32995" xml_f="32999" txt_i="11181" txt_f="11185">81.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33032" xml_f="33036" txt_i="11186" txt_f="11190">74.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33069" xml_f="33073" txt_i="11191" txt_f="11195">79.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33106" xml_f="33110" txt_i="11196" txt_f="11200">75.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33143" xml_f="33147" txt_i="11201" txt_f="11205">81.3</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="33222" xml_f="33241" txt_i="11207" txt_f="11226">Electrocardiography</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="33547" xml_f="33566" txt_i="11235" txt_f="11254"> R wave in aVL (mm)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33599" xml_f="33606" txt_i="11255" txt_f="11262">4.2 (3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33639" xml_f="33646" txt_i="11263" txt_f="11270">3.7 (3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33679" xml_f="33686" txt_i="11271" txt_f="11278">6.1 (4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33719" xml_f="33726" txt_i="11279" txt_f="11286">3.7 (3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33759" xml_f="33766" txt_i="11287" txt_f="11294">5.9 (4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33799" xml_f="33806" txt_i="11295" txt_f="11302">3.7 (3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33839" xml_f="33846" txt_i="11303" txt_f="11310">5.9 (4)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="33901" xml_f="33911" txt_i="11311" txt_f="11318">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="33953" xml_f="33965" txt_i="11319" txt_f="11331"> S wave in V</offsets><sub><offsets xml_i="33970" xml_f="33971" txt_i="11331" txt_f="11332">3</offsets></sub><offsets xml_i="33977" xml_f="33982" txt_i="11332" txt_f="11337"> (mm)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34015" xml_f="34023" txt_i="11338" txt_f="11346">10.3 (6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34056" xml_f="34063" txt_i="11347" txt_f="11354">9.2 (4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34096" xml_f="34104" txt_i="11355" txt_f="11363">14.4 (7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34137" xml_f="34144" txt_i="11364" txt_f="11371">9.0 (4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34177" xml_f="34183" txt_i="11372" txt_f="11378">15 (7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34216" xml_f="34223" txt_i="11379" txt_f="11386">9.1 (4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34256" xml_f="34266" txt_i="11387" txt_f="11397">14.5 (7.2)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="34321" xml_f="34331" txt_i="11398" txt_f="11405">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="34373" xml_f="34384" txt_i="11406" txt_f="11417"> Strain (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34417" xml_f="34421" txt_i="11418" txt_f="11422">16.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34454" xml_f="34455" txt_i="11423" txt_f="11424">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34488" xml_f="34492" txt_i="11425" txt_f="11429">72.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34525" xml_f="34526" txt_i="11430" txt_f="11431">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34559" xml_f="34563" txt_i="11432" txt_f="11436">73.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34596" xml_f="34597" txt_i="11437" txt_f="11438">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34630" xml_f="34634" txt_i="11439" txt_f="11443">72.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34667" xml_f="34668" txt_i="11444" txt_f="11445">-</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="34710" xml_f="34730" txt_i="11446" txt_f="11466">LV ejection fraction</offsets><xref ref-type="table-fn" rid="tblfn4"><sup><offsets xml_i="34774" xml_f="34775" txt_i="11466" txt_f="11467">b</offsets></sup></xref></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="35074" xml_f="35084" txt_i="11475" txt_f="11482">&lt; 0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35126" xml_f="35136" txt_i="11483" txt_f="11493"> ≤ 40% (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35169" xml_f="35173" txt_i="11494" txt_f="11498">23.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35206" xml_f="35210" txt_i="11499" txt_f="11503">19.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35243" xml_f="35247" txt_i="11504" txt_f="11508">35.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35280" xml_f="35284" txt_i="11509" txt_f="11513">17.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35317" xml_f="35321" txt_i="11514" txt_f="11518">36.6</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35354" xml_f="35358" txt_i="11519" txt_f="11523">19.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35391" xml_f="35395" txt_i="11524" txt_f="11528">35.5</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35470" xml_f="35483" txt_i="11530" txt_f="11540"> &gt; 40% (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35516" xml_f="35520" txt_i="11541" txt_f="11545">77.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35553" xml_f="35557" txt_i="11546" txt_f="11550">81.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35590" xml_f="35594" txt_i="11551" txt_f="11555">64.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35627" xml_f="35631" txt_i="11556" txt_f="11560">82.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35664" xml_f="35668" txt_i="11561" txt_f="11565">63.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35701" xml_f="35705" txt_i="11566" txt_f="11570">80.5</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35738" xml_f="35742" txt_i="11571" txt_f="11575">64.5</offsets></td><td rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p><offsets xml_i="35837" xml_f="35902" txt_i="11577" txt_f="11642">Continuous data are reported as mean (SD); categorical data as %.</offsets></p></fn><fn id="tblfn2"><p><offsets xml_i="35930" xml_f="36196" txt_i="11643" txt_f="11909">LVH −, absence of left ventricular hypertrophy; LVH + , presence of left ventricular hypertrophy; bid, twice daily; BMI, body mass index; CrCl, creatinine clearance; CNS, central nervous system; BP, blood pressure; VKA, vitamin K antagonists; SD, standard deviation.</offsets></p></fn><fn id="tblfn3"><label><offsets xml_i="36228" xml_f="36229" txt_i="11910" txt_f="11911">a</offsets></label><p><offsets xml_i="36240" xml_f="36278" txt_i="11911" txt_f="11949">aspirin, clopidogrel, or dipyridamole.</offsets></p></fn><fn id="tblfn4"><label><offsets xml_i="36310" xml_f="36311" txt_i="11950" txt_f="11951">b</offsets></label><p><offsets xml_i="36322" xml_f="36377" txt_i="11951" txt_f="12006">by echocardiography, radionuclide study or angiography.</offsets></p></fn><fn id="tblfn5"><label><offsets xml_i="36409" xml_f="36410" txt_i="12007" txt_f="12008">*</offsets></label><p><italic><offsets xml_i="36429" xml_f="36430" txt_i="12008" txt_f="12009">P</offsets></italic><offsets xml_i="36439" xml_f="36455" txt_i="12009" txt_f="12025">-value based on </offsets><italic><offsets xml_i="36463" xml_f="36464" txt_i="12025" txt_f="12026">t</offsets></italic><offsets xml_i="36473" xml_f="36483" txt_i="12026" txt_f="12036">-test or χ</offsets><sup><offsets xml_i="36488" xml_f="36489" txt_i="12036" txt_f="12037">2</offsets></sup><offsets xml_i="36495" xml_f="36541" txt_i="12037" txt_f="12083"> test comparing patients with vs. without LVH.</offsets></p></fn></table-wrap-foot></table-wrap></p></sec><sec><title><offsets xml_i="36603" xml_f="36617" txt_i="12086" txt_f="12100">Outcome events</offsets></title><p><offsets xml_i="36628" xml_f="37070" txt_i="12101" txt_f="12543">Median follow-up time was 2.0 years. During this period, 327 patients (3.2%) developed a primary outcome event, a composite of stroke or systemic embolism. Overall, there were 303 patients (2.9%) who developed a stroke, 261 patients experienced at least one ischaemic stroke and 47 a haemorrhagic stroke. Overall, 497 patients (4.8%) died of cardiovascular causes and 778 patients (7.5%) died from any cause (including cardiovascular causes).</offsets></p><p><offsets xml_i="37077" xml_f="37089" txt_i="12544" txt_f="12556">As shown in </offsets><italic><offsets xml_i="37097" xml_f="37102" txt_i="12556" txt_f="12561">Table</offsets></italic><xref ref-type="table" rid="eux022-T2"><italic><offsets xml_i="37158" xml_f="37159" txt_i="12561" txt_f="12562">2</offsets></italic></xref><offsets xml_i="37175" xml_f="37180" txt_i="12562" txt_f="12567"> and </offsets><italic><offsets xml_i="37188" xml_f="37195" txt_i="12567" txt_f="12574">Figure </offsets></italic><xref ref-type="fig" rid="eux022-F2"><italic><offsets xml_i="37249" xml_f="37250" txt_i="12574" txt_f="12575">2</offsets></italic></xref><offsets xml_i="37266" xml_f="37426" txt_i="12575" txt_f="12735">, in patients without LVH the rates of primary outcome were 1.59% per year with warfarin, 1.60% with dabigatran 110 mg (HR vs. warfarin 1.01, 95% CI 0.75–1.36; </offsets><italic><offsets xml_i="37434" xml_f="37435" txt_i="12735" txt_f="12736">P</offsets></italic><offsets xml_i="37444" xml_f="37527" txt_i="12736" txt_f="12819"> = 0.95) and 1.08% with dabigatran 150 mg (HR vs. warfarin 0.68, 95% CI 0.49–0.95; </offsets><italic><offsets xml_i="37535" xml_f="37536" txt_i="12819" txt_f="12820">P</offsets></italic><offsets xml_i="37545" xml_f="37786" txt_i="12820" txt_f="13061"> = 0.023). In patients with LVH, the rates of primary outcome were 3.21% per year with warfarin, 1.69% with dabigatran 110 mg (HR vs. warfarin 0.52, 95% CI 0.32–0.84) and 1.55% with dabigatran 150 mg (HR vs. warfarin 0.48, 95% CI 0.29–0.78).</offsets></p><p><offsets xml_i="37793" xml_f="37915" txt_i="13062" txt_f="13184">For the primary RE-LY outcome, there was a significant interaction between LVH status and dabigatran 110 mg vs. warfarin (</offsets><italic><offsets xml_i="37923" xml_f="37924" txt_i="13184" txt_f="13185">P</offsets></italic><offsets xml_i="37933" xml_f="37988" txt_i="13185" txt_f="13240"> = 0.021), while there was no significant interaction (</offsets><italic><offsets xml_i="37996" xml_f="37997" txt_i="13240" txt_f="13241">P</offsets></italic><offsets xml_i="38006" xml_f="38071" txt_i="13241" txt_f="13306"> = 0.244) between LVH status and dabigatran 150 mg vs. warfarin.
</offsets><table-wrap id="eux022-T2" orientation="portrait" position="float"><label><offsets xml_i="38145" xml_f="38152" txt_i="13306" txt_f="13313">Table 2</offsets></label><caption><p><offsets xml_i="38172" xml_f="38236" txt_i="13313" txt_f="13377">Outcome events in the population. Results of univariate analysis</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"></th><th rowspan="2" colspan="1"><offsets xml_i="38359" xml_f="38362" txt_i="13378" txt_f="13381">LVH</offsets></th><th colspan="2" rowspan="1"><offsets xml_i="38395" xml_f="38412" txt_i="13381" txt_f="13398">Dabigatran 110 mg</offsets><hr></hr></th><th colspan="2" rowspan="1"><offsets xml_i="38454" xml_f="38471" txt_i="13398" txt_f="13415">Dabigatran 150 mg</offsets><hr></hr></th><th colspan="2" rowspan="1"><offsets xml_i="38513" xml_f="38521" txt_i="13415" txt_f="13423">Warfarin</offsets><hr></hr></th><th colspan="2" rowspan="1"><offsets xml_i="38563" xml_f="38584" txt_i="13423" txt_f="13444">Hazard Ratio (95% CI)</offsets><hr></hr></th><th rowspan="1" colspan="1"><italic><offsets xml_i="38634" xml_f="38635" txt_i="13444" txt_f="13445">P</offsets></italic><offsets xml_i="38644" xml_f="38650" txt_i="13445" txt_f="13451">-value</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="38691" xml_f="38692" txt_i="13451" txt_f="13452">P</offsets></italic><offsets xml_i="38701" xml_f="38707" txt_i="13452" txt_f="13458">-value</offsets></th><th colspan="2" rowspan="1"><italic><offsets xml_i="38748" xml_f="38749" txt_i="13458" txt_f="13459">P</offsets></italic><offsets xml_i="38758" xml_f="38780" txt_i="13459" txt_f="13481">-value for interaction</offsets><hr></hr></th></tr><tr><th rowspan="1" colspan="1"><italic><offsets xml_i="38839" xml_f="38840" txt_i="13481" txt_f="13482">N</offsets></italic></th><th rowspan="1" colspan="1"><offsets xml_i="38882" xml_f="38886" txt_i="13482" txt_f="13486">%/yr</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="38927" xml_f="38928" txt_i="13486" txt_f="13487">N</offsets></italic></th><th rowspan="1" colspan="1"><offsets xml_i="38970" xml_f="38974" txt_i="13487" txt_f="13491">%/yr</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="39015" xml_f="39016" txt_i="13491" txt_f="13492">N</offsets></italic></th><th rowspan="1" colspan="1"><offsets xml_i="39058" xml_f="39062" txt_i="13492" txt_f="13496">%/yr</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="39095" xml_f="39116" txt_i="13496" txt_f="13517">D 110 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="39149" xml_f="39170" txt_i="13517" txt_f="13538">D 150 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="39203" xml_f="39224" txt_i="13538" txt_f="13559">D 110 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="39257" xml_f="39278" txt_i="13559" txt_f="13580">D 150 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="39311" xml_f="39332" txt_i="13580" txt_f="13601">D 110 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="39365" xml_f="39386" txt_i="13601" txt_f="13622">D 150 mg vs. warfarin</offsets></th></tr></thead><tbody><tr><td rowspan="2" colspan="1"><offsets xml_i="39443" xml_f="39470" txt_i="13622" txt_f="13649">Stroke or systemic embolism</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39503" xml_f="39509" txt_i="13650" txt_f="13656">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39542" xml_f="39544" txt_i="13657" txt_f="13659">87</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39577" xml_f="39581" txt_i="13660" txt_f="13664">1.60</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39614" xml_f="39616" txt_i="13665" txt_f="13667">58</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39649" xml_f="39653" txt_i="13668" txt_f="13672">1.08</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39686" xml_f="39688" txt_i="13673" txt_f="13675">84</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39721" xml_f="39725" txt_i="13676" txt_f="13680">1.59</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39758" xml_f="39774" txt_i="13681" txt_f="13697">1.01 (0.75–1.36)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39807" xml_f="39823" txt_i="13698" txt_f="13714">0.68 (0.49–0.95)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39856" xml_f="39862" txt_i="13715" txt_f="13721">0.9504</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39895" xml_f="39901" txt_i="13722" txt_f="13728">0.0231</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39934" xml_f="39940" txt_i="13729" txt_f="13735">0.0215</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39973" xml_f="39979" txt_i="13736" txt_f="13742">0.2448</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="40021" xml_f="40028" txt_i="13743" txt_f="13750">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40061" xml_f="40063" txt_i="13751" txt_f="13753">26</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40096" xml_f="40100" txt_i="13754" txt_f="13758">1.69</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40133" xml_f="40135" txt_i="13759" txt_f="13761">24</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40168" xml_f="40172" txt_i="13762" txt_f="13766">1.55</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40205" xml_f="40207" txt_i="13767" txt_f="13769">48</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40240" xml_f="40244" txt_i="13770" txt_f="13774">3.21</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40277" xml_f="40293" txt_i="13775" txt_f="13791">0.52 (0.32–0.84)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40326" xml_f="40342" txt_i="13792" txt_f="13808">0.48 (0.29–0.78)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40375" xml_f="40381" txt_i="13809" txt_f="13815">0.0076</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40414" xml_f="40420" txt_i="13816" txt_f="13822">0.0031</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" colspan="1"><offsets xml_i="40528" xml_f="40538" txt_i="13825" txt_f="13835">Any stroke</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40571" xml_f="40577" txt_i="13836" txt_f="13842">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40610" xml_f="40612" txt_i="13843" txt_f="13845">81</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40645" xml_f="40649" txt_i="13846" txt_f="13850">1.49</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40682" xml_f="40684" txt_i="13851" txt_f="13853">54</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40717" xml_f="40721" txt_i="13854" txt_f="13858">1.00</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40754" xml_f="40756" txt_i="13859" txt_f="13861">77</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40789" xml_f="40793" txt_i="13862" txt_f="13866">1.45</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40826" xml_f="40842" txt_i="13867" txt_f="13883">1.03 (0.75–1.40)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40875" xml_f="40891" txt_i="13884" txt_f="13900">0.69 (0.49–0.98)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40924" xml_f="40930" txt_i="13901" txt_f="13907">0.8724</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40963" xml_f="40969" txt_i="13908" txt_f="13914">0.0355</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41002" xml_f="41008" txt_i="13915" txt_f="13921">0.0162</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41041" xml_f="41047" txt_i="13922" txt_f="13928">0.1467</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="41089" xml_f="41096" txt_i="13929" txt_f="13936">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41129" xml_f="41131" txt_i="13937" txt_f="13939">24</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41164" xml_f="41168" txt_i="13940" txt_f="13944">1.56</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41201" xml_f="41203" txt_i="13945" txt_f="13947">21</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41236" xml_f="41240" txt_i="13948" txt_f="13952">1.36</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41273" xml_f="41275" txt_i="13953" txt_f="13955">46</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41308" xml_f="41312" txt_i="13956" txt_f="13960">3.08</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41345" xml_f="41361" txt_i="13961" txt_f="13977">0.50 (0.31–0.82)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41394" xml_f="41410" txt_i="13978" txt_f="13994">0.43 (0.26–0.73)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41443" xml_f="41449" txt_i="13995" txt_f="14001">0.0062</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41482" xml_f="41488" txt_i="14002" txt_f="14008">0.0016</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" colspan="1"><offsets xml_i="41596" xml_f="41611" txt_i="14011" txt_f="14026">All-cause death</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41644" xml_f="41650" txt_i="14027" txt_f="14033">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41683" xml_f="41686" txt_i="14034" txt_f="14037">166</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41719" xml_f="41723" txt_i="14038" txt_f="14042">3.05</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41756" xml_f="41759" txt_i="14043" txt_f="14046">151</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41792" xml_f="41796" txt_i="14047" txt_f="14051">2.81</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41829" xml_f="41832" txt_i="14052" txt_f="14055">185</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41865" xml_f="41869" txt_i="14056" txt_f="14060">3.49</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41902" xml_f="41918" txt_i="14061" txt_f="14077">0.87 (0.71–1.07)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41951" xml_f="41967" txt_i="14078" txt_f="14094">0.80 (0.65–0.99)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42000" xml_f="42006" txt_i="14095" txt_f="14101">0.1938</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42039" xml_f="42045" txt_i="14102" txt_f="14108">0.0448</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42078" xml_f="42084" txt_i="14109" txt_f="14115">0.9329</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42117" xml_f="42123" txt_i="14116" txt_f="14122">0.7406</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="42264" xml_f="42271" txt_i="14126" txt_f="14133">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42304" xml_f="42306" txt_i="14134" txt_f="14136">88</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42339" xml_f="42343" txt_i="14137" txt_f="14141">5.73</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42376" xml_f="42378" txt_i="14142" txt_f="14144">88</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42411" xml_f="42415" txt_i="14145" txt_f="14149">5.69</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42448" xml_f="42451" txt_i="14150" txt_f="14153">100</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42484" xml_f="42488" txt_i="14154" txt_f="14158">6.70</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42521" xml_f="42537" txt_i="14159" txt_f="14175">0.85 (0.64–1.14)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42570" xml_f="42586" txt_i="14176" txt_f="14192">0.85 (0.64–1.13)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42619" xml_f="42625" txt_i="14193" txt_f="14199">0.2783</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42658" xml_f="42664" txt_i="14200" txt_f="14206">0.2667</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" colspan="1"><offsets xml_i="42772" xml_f="42786" txt_i="14209" txt_f="14223">Vascular death</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42819" xml_f="42825" txt_i="14224" txt_f="14230">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42858" xml_f="42860" txt_i="14231" txt_f="14233">90</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42893" xml_f="42897" txt_i="14234" txt_f="14238">1.65</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42930" xml_f="42932" txt_i="14239" txt_f="14241">93</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="42965" xml_f="42969" txt_i="14242" txt_f="14246">1.73</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43002" xml_f="43005" txt_i="14247" txt_f="14250">107</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43038" xml_f="43042" txt_i="14251" txt_f="14255">2.02</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43075" xml_f="43091" txt_i="14256" txt_f="14272">0.82 (0.62–1.08)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43124" xml_f="43140" txt_i="14273" txt_f="14289">0.85 (0.65–1.13)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43173" xml_f="43179" txt_i="14290" txt_f="14296">0.1595</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43212" xml_f="43218" txt_i="14297" txt_f="14303">0.2656</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43251" xml_f="43257" txt_i="14304" txt_f="14310">0.8121</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43290" xml_f="43296" txt_i="14311" txt_f="14317">0.5317</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="43371" xml_f="43378" txt_i="14319" txt_f="14326">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43411" xml_f="43413" txt_i="14327" txt_f="14329">69</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43446" xml_f="43450" txt_i="14330" txt_f="14334">4.49</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43483" xml_f="43485" txt_i="14335" txt_f="14337">60</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43518" xml_f="43522" txt_i="14338" txt_f="14342">3.88</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43555" xml_f="43557" txt_i="14343" txt_f="14345">78</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43590" xml_f="43594" txt_i="14346" txt_f="14350">5.22</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43627" xml_f="43643" txt_i="14351" txt_f="14367">0.86 (0.62–1.19)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43676" xml_f="43692" txt_i="14368" txt_f="14384">0.74 (0.53–1.04)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43725" xml_f="43731" txt_i="14385" txt_f="14391">0.3551</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43764" xml_f="43770" txt_i="14392" txt_f="14398">0.0819</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="tblfn6"><p><offsets xml_i="43898" xml_f="43958" txt_i="14401" txt_f="14461">LVH, left ventricular hypertrophy; CI, confidence interval; </offsets><italic><offsets xml_i="43966" xml_f="43967" txt_i="14461" txt_f="14462">N</offsets></italic><offsets xml_i="43976" xml_f="44022" txt_i="14462" txt_f="14508">, number of patients; yr, year; D, dabigatran.</offsets></p></fn></table-wrap-foot></table-wrap></p><p><offsets xml_i="44069" xml_f="44082" txt_i="14510" txt_f="14523">Stroke rate (</offsets><italic><offsets xml_i="44090" xml_f="44097" txt_i="14523" txt_f="14530">Figure </offsets></italic><xref ref-type="fig" rid="eux022-F2"><italic><offsets xml_i="44151" xml_f="44152" txt_i="14530" txt_f="14531">2</offsets></italic></xref><offsets xml_i="44168" xml_f="44442" txt_i="14531" txt_f="14805">) did not differ between the dabigatran 110 mg group and the warfarin group in the patients without LVH (1.49% vs. 1.45% per year), while it was considerably lower in the dabigatran 110 mg group than in the warfarin group in the patients with LVH (1.56% vs. 3.08% per year, </offsets><italic><offsets xml_i="44450" xml_f="44451" txt_i="14805" txt_f="14806">P</offsets></italic><offsets xml_i="44460" xml_f="44571" txt_i="14806" txt_f="14917"> = 0.0062). For stroke, the interaction between LVH status and dabigatran 110 mg vs. warfarin was significant (</offsets><italic><offsets xml_i="44579" xml_f="44580" txt_i="14917" txt_f="14918">P</offsets></italic><offsets xml_i="44589" xml_f="44699" txt_i="14918" txt_f="15028"> = 0.016), whereas the interaction between LVH status and dabigatran 150 mg vs. warfarin was not significant.
</offsets></p><fig id="eux022-F2" orientation="portrait" position="float"><label><offsets xml_i="44770" xml_f="44778" txt_i="15029" txt_f="15037">Figure 2</offsets></label><caption><p><offsets xml_i="44798" xml_f="44946" txt_i="15037" txt_f="15185">Interaction between left ventricular hypertrophy and effects of dabigatran vs. warfarin. CI, confidence interval; LVH, left ventricular hypertrophy.</offsets></p></caption><graphic xlink:href="eux022f2"></graphic></fig><p><offsets xml_i="45010" xml_f="45147" txt_i="15186" txt_f="15323">Neither all-cause death nor vascular death showed statistically significant interactions between LVH status and dabigatran 110 or 150 mg.</offsets></p><p><offsets xml_i="45154" xml_f="45155" txt_i="15324" txt_f="15325">
</offsets><italic><offsets xml_i="45163" xml_f="45170" txt_i="15325" txt_f="15332">Figure </offsets></italic><offsets xml_i="45179" xml_f="45180" txt_i="15332" txt_f="15333">
</offsets><xref ref-type="fig" rid="eux022-F3"><offsets xml_i="45217" xml_f="45218" txt_i="15333" txt_f="15334">
</offsets><italic><offsets xml_i="45226" xml_f="45227" txt_i="15334" txt_f="15335">3</offsets></italic><offsets xml_i="45236" xml_f="45237" txt_i="15335" txt_f="15336">
</offsets></xref><offsets xml_i="45244" xml_f="45373" txt_i="15336" txt_f="15465"> shows the Kaplan–Meier failure curves for the primary outcome in the three randomized groups for patients without and with LVH.
</offsets></p><fig id="eux022-F3" orientation="portrait" position="float"><label><offsets xml_i="45444" xml_f="45452" txt_i="15466" txt_f="15474">Figure 3</offsets></label><caption><p><offsets xml_i="45472" xml_f="45748" txt_i="15474" txt_f="15750">Cumulative incidence of the primary RE-LY study outcome in the three randomized groups in patients without (left panel) and with (right panel) left ventricular hypertrophy. CI, confidence interval; DE, dabigatran etexilate; HR, hazard ratio; LVH, left ventricular hypertrophy.</offsets></p></caption><graphic xlink:href="eux022f3"></graphic></fig><fig id="eux022-F4" orientation="portrait" position="float"><label><offsets xml_i="45876" xml_f="45884" txt_i="15751" txt_f="15759">Figure 4</offsets></label><caption><p><offsets xml_i="45904" xml_f="46076" txt_i="15759" txt_f="15931">Distribution of the time in therapeutic range in the warfarin group according to the absence or presence of left ventricular hypertrophy. LVH, left ventricular hypertrophy.</offsets></p></caption><graphic xlink:href="eux022f4"></graphic></fig><p><offsets xml_i="46140" xml_f="46163" txt_i="15932" txt_f="15955">A multivariable model (</offsets><italic><offsets xml_i="46171" xml_f="46177" txt_i="15955" txt_f="15961">Table </offsets></italic><xref ref-type="table" rid="eux022-T3"><italic><offsets xml_i="46233" xml_f="46234" txt_i="15961" txt_f="15962">3</offsets></italic></xref><offsets xml_i="46250" xml_f="46269" txt_i="15962" txt_f="15981">) including the CHA</offsets><sub><offsets xml_i="46274" xml_f="46275" txt_i="15981" txt_f="15982">2</offsets></sub><offsets xml_i="46281" xml_f="46283" txt_i="15982" txt_f="15984">DS</offsets><sub><offsets xml_i="46288" xml_f="46289" txt_i="15984" txt_f="15985">2</offsets></sub><offsets xml_i="46295" xml_f="46647" txt_i="15985" txt_f="16337">VASc score, body mass index, valvular heart disease, current smoking, use of digoxin, permanent AF, randomized treatment and glomerular filtration rate as additional explanatory covariables, confirmed a significant interaction between LVH status and dabigatran 110 mg on the risk of primary outcome and any stroke. When the single components of the CHA</offsets><sub><offsets xml_i="46652" xml_f="46653" txt_i="16337" txt_f="16338">2</offsets></sub><offsets xml_i="46659" xml_f="46661" txt_i="16338" txt_f="16340">DS</offsets><sub><offsets xml_i="46666" xml_f="46667" txt_i="16340" txt_f="16341">2</offsets></sub><offsets xml_i="46673" xml_f="46740" txt_i="16341" txt_f="16408">VASc score entered the model in addition to the other covariables (</offsets><italic><offsets xml_i="46748" xml_f="46754" txt_i="16408" txt_f="16414">Table </offsets></italic><xref ref-type="table" rid="eux022-T4"><italic><offsets xml_i="46810" xml_f="46811" txt_i="16414" txt_f="16415">4</offsets></italic></xref><offsets xml_i="46827" xml_f="46931" txt_i="16415" txt_f="16519">), the significant interaction between LVH status and dabigatran 110 mg on the risk of primary outcome (</offsets><italic><offsets xml_i="46939" xml_f="46940" txt_i="16519" txt_f="16520">P</offsets></italic><offsets xml_i="46949" xml_f="46976" txt_i="16520" txt_f="16547"> = 0.0362) and any stroke (</offsets><italic><offsets xml_i="46984" xml_f="46985" txt_i="16547" txt_f="16548">P</offsets></italic><offsets xml_i="46994" xml_f="47148" txt_i="16548" txt_f="16702"> = 0.0247) was confirmed. In the above model, congestive heart failure showed an independent association with all-cause death (HR 1.61; 95% CI 1.34–1.93; </offsets><italic><offsets xml_i="47156" xml_f="47157" txt_i="16702" txt_f="16703">P</offsets></italic><offsets xml_i="47166" xml_f="47226" txt_i="16703" txt_f="16760"> &lt; 0.001) and vascular death (HR 2.02; 95% CI 1.61–2.55; </offsets><italic><offsets xml_i="47234" xml_f="47235" txt_i="16760" txt_f="16761">P</offsets></italic><offsets xml_i="47244" xml_f="47298" txt_i="16761" txt_f="16812"> &lt; 0.001), but not with the primary RE-LY outcome (</offsets><italic><offsets xml_i="47306" xml_f="47307" txt_i="16812" txt_f="16813">P</offsets></italic><offsets xml_i="47316" xml_f="47337" txt_i="16813" txt_f="16834"> = 9196) and stroke (</offsets><italic><offsets xml_i="47345" xml_f="47346" txt_i="16834" txt_f="16835">P</offsets></italic><offsets xml_i="47355" xml_f="47424" txt_i="16835" txt_f="16904"> = 0.9081) in the comparison between dabigatran 110 mg and warfarin.
</offsets><table-wrap id="eux022-T3" orientation="portrait" position="float"><label><offsets xml_i="47498" xml_f="47505" txt_i="16904" txt_f="16911">Table 3</offsets></label><caption><p><offsets xml_i="47525" xml_f="47591" txt_i="16911" txt_f="16977">Outcome events in the population. Results of multivariate analysis</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"></th><th rowspan="2" colspan="1"><offsets xml_i="47714" xml_f="47717" txt_i="16978" txt_f="16981">LVH</offsets></th><th colspan="6" rowspan="1"><offsets xml_i="47750" xml_f="47762" txt_i="16981" txt_f="16993">Hazard Ratio</offsets><hr></hr></th></tr><tr><th rowspan="1" colspan="1"><offsets xml_i="47813" xml_f="47834" txt_i="16993" txt_f="17014">D 110 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="47875" xml_f="47876" txt_i="17014" txt_f="17015">P</offsets></italic><offsets xml_i="47885" xml_f="47891" txt_i="17015" txt_f="17021">-value</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="47932" xml_f="47933" txt_i="17021" txt_f="17022">P</offsets></italic><offsets xml_i="47942" xml_f="47964" txt_i="17022" txt_f="17044">-value for interaction</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="47997" xml_f="48018" txt_i="17044" txt_f="17065">D 150 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="48059" xml_f="48060" txt_i="17065" txt_f="17066">P</offsets></italic><offsets xml_i="48069" xml_f="48075" txt_i="17066" txt_f="17072">-value</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="48116" xml_f="48117" txt_i="17072" txt_f="17073">P</offsets></italic><offsets xml_i="48126" xml_f="48148" txt_i="17073" txt_f="17095">-value for interaction</offsets></th></tr></thead><tbody><tr><td rowspan="2" colspan="1"><offsets xml_i="48205" xml_f="48232" txt_i="17095" txt_f="17122">Stroke or systemic embolism</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48265" xml_f="48271" txt_i="17123" txt_f="17129">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48304" xml_f="48320" txt_i="17130" txt_f="17146">1.03 (0.76–1.39)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48353" xml_f="48359" txt_i="17147" txt_f="17153">0.8704</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48392" xml_f="48398" txt_i="17154" txt_f="17160">0.0246</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48431" xml_f="48447" txt_i="17161" txt_f="17177">0.69 (0.50–0.97)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48480" xml_f="48486" txt_i="17178" txt_f="17184">0.0329</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48519" xml_f="48525" txt_i="17185" txt_f="17191">0.2734</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="48567" xml_f="48574" txt_i="17192" txt_f="17199">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48607" xml_f="48623" txt_i="17200" txt_f="17216">0.54 (0.33–0.87)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48656" xml_f="48662" txt_i="17217" txt_f="17223">0.0106</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="48728" xml_f="48744" txt_i="17225" txt_f="17241">0.50 (0.30–0.81)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48777" xml_f="48783" txt_i="17242" txt_f="17248">0.0053</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" colspan="1"><offsets xml_i="48891" xml_f="48901" txt_i="17251" txt_f="17261">Any stroke</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48934" xml_f="48940" txt_i="17262" txt_f="17268">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48973" xml_f="48989" txt_i="17269" txt_f="17285">1.04 (0.76–1.43)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49022" xml_f="49028" txt_i="17286" txt_f="17292">0.1757</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49061" xml_f="49067" txt_i="17293" txt_f="17299">0.0309</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49100" xml_f="49116" txt_i="17300" txt_f="17316">0.70 (0.50–1.00)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49149" xml_f="49155" txt_i="17317" txt_f="17323">0.0494</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49188" xml_f="49194" txt_i="17324" txt_f="17330">0.1626</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="49236" xml_f="49243" txt_i="17331" txt_f="17338">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49276" xml_f="49292" txt_i="17339" txt_f="17355">0.64 (0.38–1.07)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49325" xml_f="49331" txt_i="17356" txt_f="17362">0.0903</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="49397" xml_f="49413" txt_i="17364" txt_f="17380">0.45 (0.27–0.76)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49446" xml_f="49452" txt_i="17381" txt_f="17387">0.0026</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" colspan="1"><offsets xml_i="49560" xml_f="49575" txt_i="17390" txt_f="17405">All-cause death</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49608" xml_f="49614" txt_i="17406" txt_f="17412">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49647" xml_f="49663" txt_i="17413" txt_f="17429">0.86 (0.70–1.07)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49696" xml_f="49702" txt_i="17430" txt_f="17436">0.1773</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49735" xml_f="49741" txt_i="17437" txt_f="17443">0.9953</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49774" xml_f="49790" txt_i="17444" txt_f="17460">0.80 (0.65–1.00)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49823" xml_f="49829" txt_i="17461" txt_f="17467">0.0471</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49862" xml_f="49868" txt_i="17468" txt_f="17474">0.5854</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="49910" xml_f="49917" txt_i="17475" txt_f="17482">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49950" xml_f="49966" txt_i="17483" txt_f="17499">0.86 (0.65–1.16)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49999" xml_f="50005" txt_i="17500" txt_f="17506">0.3238</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="50071" xml_f="50087" txt_i="17508" txt_f="17524">0.89 (0.66–1.18)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50120" xml_f="50126" txt_i="17525" txt_f="17531">0.4197</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" colspan="1"><offsets xml_i="50234" xml_f="50248" txt_i="17534" txt_f="17548">Vascular death</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50281" xml_f="50287" txt_i="17549" txt_f="17555">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50320" xml_f="50336" txt_i="17556" txt_f="17572">0.82 (0.62–1.08)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50369" xml_f="50375" txt_i="17573" txt_f="17579">0.1595</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50408" xml_f="50414" txt_i="17580" txt_f="17586">0.7352</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50447" xml_f="50463" txt_i="17587" txt_f="17603">0.86 (0.65–1.14)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50496" xml_f="50502" txt_i="17604" txt_f="17610">0.3058</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50535" xml_f="50541" txt_i="17611" txt_f="17617">0.6656</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="50583" xml_f="50590" txt_i="17618" txt_f="17625">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50623" xml_f="50639" txt_i="17626" txt_f="17642">0.86 (0.65–1.16)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50672" xml_f="50678" txt_i="17643" txt_f="17649">0.3238</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="50744" xml_f="50760" txt_i="17651" txt_f="17667">0.78 (0.56–1.10)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50793" xml_f="50799" txt_i="17668" txt_f="17674">0.1611</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="tblfn7"><p><offsets xml_i="50927" xml_f="50943" txt_i="17677" txt_f="17693">Adjusted for CHA</offsets><sub><offsets xml_i="50948" xml_f="50949" txt_i="17693" txt_f="17694">2</offsets></sub><offsets xml_i="50955" xml_f="50957" txt_i="17694" txt_f="17696">DS</offsets><sub><offsets xml_i="50962" xml_f="50963" txt_i="17696" txt_f="17697">2</offsets></sub><offsets xml_i="50969" xml_f="51199" txt_i="17697" txt_f="17927">VASc score, body mass index, current smoking at entry, glomerular filtration rate, use of digoxin at entry, valvular heart disease at entry, permanent AF at entry, randomized treatment, LVH, treatment, LVH x treatment interaction.</offsets></p></fn><fn id="tblfn8"><p><offsets xml_i="51227" xml_f="51301" txt_i="17928" txt_f="18002">LVH, left ventricular hypertrophy; D, dabigatran; AF, atrial fibrillation.</offsets></p></fn></table-wrap-foot></table-wrap><table-wrap id="eux022-T4" orientation="portrait" position="float"><label><offsets xml_i="51415" xml_f="51422" txt_i="18003" txt_f="18010">Table 4</offsets></label><caption><p><offsets xml_i="51442" xml_f="51508" txt_i="18010" txt_f="18076">Outcome events in the population. Results of multivariate analysis</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"></th><th rowspan="2" colspan="1"><offsets xml_i="51631" xml_f="51634" txt_i="18077" txt_f="18080">LVH</offsets></th><th colspan="6" rowspan="1"><offsets xml_i="51667" xml_f="51679" txt_i="18080" txt_f="18092">Hazard Ratio</offsets><hr></hr></th></tr><tr><th rowspan="1" colspan="1"><offsets xml_i="51730" xml_f="51751" txt_i="18092" txt_f="18113">D 110 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="51792" xml_f="51793" txt_i="18113" txt_f="18114">P</offsets></italic><offsets xml_i="51802" xml_f="51808" txt_i="18114" txt_f="18120">-value</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="51849" xml_f="51850" txt_i="18120" txt_f="18121">P</offsets></italic><offsets xml_i="51859" xml_f="51881" txt_i="18121" txt_f="18143"> value for interaction</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="51914" xml_f="51935" txt_i="18143" txt_f="18164">D 150 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="51976" xml_f="51977" txt_i="18164" txt_f="18165">P</offsets></italic><offsets xml_i="51986" xml_f="51992" txt_i="18165" txt_f="18171">-value</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="52033" xml_f="52034" txt_i="18171" txt_f="18172">P</offsets></italic><offsets xml_i="52043" xml_f="52065" txt_i="18172" txt_f="18194">-value for interaction</offsets></th></tr></thead><tbody><tr><td rowspan="2" colspan="1"><offsets xml_i="52122" xml_f="52149" txt_i="18194" txt_f="18221">Stroke or systemic embolism</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52182" xml_f="52188" txt_i="18222" txt_f="18228">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52221" xml_f="52237" txt_i="18229" txt_f="18245">1.01 (0.75–1.36)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52270" xml_f="52276" txt_i="18246" txt_f="18252">0.9500</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52309" xml_f="52315" txt_i="18253" txt_f="18259">0.0362</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52348" xml_f="52364" txt_i="18260" txt_f="18276">0.66 (0.47–0.92)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52397" xml_f="52403" txt_i="18277" txt_f="18283">0.0145</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52436" xml_f="52442" txt_i="18284" txt_f="18290">0.4186</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="52484" xml_f="52491" txt_i="18291" txt_f="18298">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52524" xml_f="52540" txt_i="18299" txt_f="18315">0.55 (0.34–0.89)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52573" xml_f="52579" txt_i="18316" txt_f="18322">0.0147</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="52645" xml_f="52661" txt_i="18324" txt_f="18340">0.51 (0.31–0.84)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52694" xml_f="52700" txt_i="18341" txt_f="18347">0.0079</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" colspan="1"><offsets xml_i="52808" xml_f="52818" txt_i="18350" txt_f="18360">Any stroke</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52851" xml_f="52857" txt_i="18361" txt_f="18367">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52890" xml_f="52906" txt_i="18368" txt_f="18384">1.03 (0.75–1.41)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52939" xml_f="52945" txt_i="18385" txt_f="18391">0.8453</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52978" xml_f="52984" txt_i="18392" txt_f="18398">0.0247</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53017" xml_f="53033" txt_i="18399" txt_f="18415">0.67 (0.47–0.95)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53066" xml_f="53072" txt_i="18416" txt_f="18422">0.0263</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53105" xml_f="53111" txt_i="18423" txt_f="18429">0.2409</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="53153" xml_f="53160" txt_i="18430" txt_f="18437">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53193" xml_f="53209" txt_i="18438" txt_f="18454">0.53 (0.32–0.86)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53242" xml_f="53248" txt_i="18455" txt_f="18461">0.0112</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="53314" xml_f="53330" txt_i="18463" txt_f="18479">0.46 (0.28–0.78)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53363" xml_f="53369" txt_i="18480" txt_f="18486">0.0035</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" colspan="1"><offsets xml_i="53477" xml_f="53492" txt_i="18489" txt_f="18504">All-cause death</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53525" xml_f="53531" txt_i="18505" txt_f="18511">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53564" xml_f="53580" txt_i="18512" txt_f="18528">0.85 (0.69–1.05)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53613" xml_f="53619" txt_i="18529" txt_f="18535">0.1374</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53652" xml_f="53658" txt_i="18536" txt_f="18542">0.9020</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53691" xml_f="53707" txt_i="18543" txt_f="18559">0.79 (0.63–0.98)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53740" xml_f="53746" txt_i="18560" txt_f="18566">0.0312</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53779" xml_f="53785" txt_i="18567" txt_f="18573">0.4560</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="53827" xml_f="53834" txt_i="18574" txt_f="18581">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53867" xml_f="53883" txt_i="18582" txt_f="18598">0.87 (0.65–1.17)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53916" xml_f="53922" txt_i="18599" txt_f="18605">0.3541</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="53988" xml_f="54004" txt_i="18607" txt_f="18623">0.90 (0.68–1.21)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54037" xml_f="54043" txt_i="18624" txt_f="18630">0.4397</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" colspan="1"><offsets xml_i="54151" xml_f="54165" txt_i="18633" txt_f="18647">Vascular death</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54198" xml_f="54204" txt_i="18648" txt_f="18654">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54237" xml_f="54253" txt_i="18655" txt_f="18671">0.80 (0.60–1.05)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54286" xml_f="54292" txt_i="18672" txt_f="18678">0.1123</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54325" xml_f="54331" txt_i="18679" txt_f="18685">0.5388</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54364" xml_f="54380" txt_i="18686" txt_f="18702">0.84 (0.63–1.11)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54413" xml_f="54419" txt_i="18703" txt_f="18709">0.2163</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54452" xml_f="54458" txt_i="18710" txt_f="18716">0.7872</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="54500" xml_f="54507" txt_i="18717" txt_f="18724">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54540" xml_f="54556" txt_i="18725" txt_f="18741">0.91 (0.66–1.27)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54589" xml_f="54595" txt_i="18742" txt_f="18748">0.5821</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="54661" xml_f="54677" txt_i="18750" txt_f="18766">0.79 (0.56–1.11)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="54710" xml_f="54716" txt_i="18767" txt_f="18773">0.1715</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="tblfn9"><p><offsets xml_i="54844" xml_f="54889" txt_i="18776" txt_f="18821">Adjusted for the single components of the CHA</offsets><sub><offsets xml_i="54894" xml_f="54895" txt_i="18821" txt_f="18822">2</offsets></sub><offsets xml_i="54901" xml_f="54903" txt_i="18822" txt_f="18824">DS</offsets><sub><offsets xml_i="54908" xml_f="54909" txt_i="18824" txt_f="18825">2</offsets></sub><offsets xml_i="54915" xml_f="55279" txt_i="18825" txt_f="19189">VASc score (congestive heart failure, hypertension, age, diabetes, prior stroke, coronary artery disease or peripheral arterial disease, gender), body mass index, current smoking at entry, glomerular filtration rate, use of digoxin at entry, valvular heart disease at entry, permanent AF at entry, randomized treatment, LVH, treatment, LVH x treatment interaction.</offsets></p></fn><fn id="tblfn10"><p><offsets xml_i="55308" xml_f="55382" txt_i="19190" txt_f="19264">LVH, left ventricular hypertrophy; D, dabigatran; AF, atrial fibrillation.</offsets></p></fn></table-wrap-foot></table-wrap></p><p><offsets xml_i="55429" xml_f="55430" txt_i="19266" txt_f="19267">
</offsets><italic><offsets xml_i="55438" xml_f="55444" txt_i="19267" txt_f="19273">Table </offsets></italic><offsets xml_i="55453" xml_f="55454" txt_i="19273" txt_f="19274">
</offsets><xref ref-type="table" rid="eux022-T5"><offsets xml_i="55493" xml_f="55494" txt_i="19274" txt_f="19275">
</offsets><italic><offsets xml_i="55502" xml_f="55503" txt_i="19275" txt_f="19276">5</offsets></italic><offsets xml_i="55512" xml_f="55513" txt_i="19276" txt_f="19277">
</offsets></xref><offsets xml_i="55520" xml_f="55789" txt_i="19277" txt_f="19546"> summarizes the bleeding events in the population. The risk of any bleeding, major bleeding and intracranial bleeding did not show any statistically significant interaction with the LVH status in the comparison of dabigatran 110 mg, or dabigatran 150 mg, vs. warfarin.
</offsets><table-wrap id="eux022-T5" orientation="portrait" position="float"><label><offsets xml_i="55863" xml_f="55870" txt_i="19546" txt_f="19553">Table 5</offsets></label><caption><p><offsets xml_i="55890" xml_f="55923" txt_i="19553" txt_f="19586">Bleeding events in the population</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1"><offsets xml_i="56046" xml_f="56049" txt_i="19587" txt_f="19590">LVH</offsets></th><th colspan="2" rowspan="1"><offsets xml_i="56082" xml_f="56092" txt_i="19590" txt_f="19600">Dabigatran</offsets></th><th colspan="2" rowspan="1"><offsets xml_i="56125" xml_f="56135" txt_i="19600" txt_f="19610">Dabigatran</offsets></th><th colspan="2" rowspan="2"><offsets xml_i="56168" xml_f="56176" txt_i="19610" txt_f="19618">Warfarin</offsets><hr></hr></th><th colspan="2" rowspan="1"><offsets xml_i="56218" xml_f="56239" txt_i="19618" txt_f="19639">Hazard Ratio (95% CI)</offsets><hr></hr></th><th rowspan="1" colspan="1"><italic><offsets xml_i="56289" xml_f="56290" txt_i="19639" txt_f="19640">P</offsets></italic><offsets xml_i="56299" xml_f="56305" txt_i="19640" txt_f="19646">-value</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="56346" xml_f="56347" txt_i="19646" txt_f="19647">P</offsets></italic><offsets xml_i="56356" xml_f="56362" txt_i="19647" txt_f="19653">-value</offsets></th><th colspan="2" rowspan="1"><italic><offsets xml_i="56403" xml_f="56404" txt_i="19653" txt_f="19654">P</offsets></italic><offsets xml_i="56413" xml_f="56423" txt_i="19654" txt_f="19664">-value for</offsets></th></tr><tr><th rowspan="2" colspan="1"></th><th rowspan="2" colspan="1"></th><th colspan="2" rowspan="1"><offsets xml_i="56531" xml_f="56537" txt_i="19664" txt_f="19670">110 mg</offsets><hr></hr></th><th colspan="2" rowspan="1"><offsets xml_i="56579" xml_f="56585" txt_i="19670" txt_f="19676">150 mg</offsets><hr></hr></th><th colspan="2" rowspan="1"></th><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1"></th><th colspan="2" rowspan="1"><offsets xml_i="56726" xml_f="56737" txt_i="19676" txt_f="19687">interaction</offsets><hr></hr></th></tr><tr><th rowspan="1" colspan="1"><italic><offsets xml_i="56796" xml_f="56797" txt_i="19687" txt_f="19688">N</offsets></italic></th><th rowspan="1" colspan="1"><offsets xml_i="56839" xml_f="56843" txt_i="19688" txt_f="19692">%/yr</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="56884" xml_f="56885" txt_i="19692" txt_f="19693">N</offsets></italic></th><th rowspan="1" colspan="1"><offsets xml_i="56927" xml_f="56931" txt_i="19693" txt_f="19697">%/yr</offsets></th><th rowspan="1" colspan="1"><italic><offsets xml_i="56972" xml_f="56973" txt_i="19697" txt_f="19698">N</offsets></italic></th><th rowspan="1" colspan="1"><offsets xml_i="57015" xml_f="57019" txt_i="19698" txt_f="19702">%/yr</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="57052" xml_f="57073" txt_i="19702" txt_f="19723">D 110 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="57106" xml_f="57127" txt_i="19723" txt_f="19744">D 150 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="57160" xml_f="57181" txt_i="19744" txt_f="19765">D 110 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="57214" xml_f="57235" txt_i="19765" txt_f="19786">D 150 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="57268" xml_f="57289" txt_i="19786" txt_f="19807">D 110 mg vs. warfarin</offsets></th><th rowspan="1" colspan="1"><offsets xml_i="57322" xml_f="57343" txt_i="19807" txt_f="19828">D 150 mg vs. warfarin</offsets></th></tr></thead><tbody><tr><td rowspan="2" colspan="1"><offsets xml_i="57400" xml_f="57412" txt_i="19828" txt_f="19840">Any bleeding</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57445" xml_f="57451" txt_i="19841" txt_f="19847">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57484" xml_f="57487" txt_i="19848" txt_f="19851">760</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57520" xml_f="57524" txt_i="19852" txt_f="19856">15.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57557" xml_f="57560" txt_i="19857" txt_f="19860">798</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57593" xml_f="57597" txt_i="19861" txt_f="19865">17.1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57630" xml_f="57633" txt_i="19866" txt_f="19869">941</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57666" xml_f="57670" txt_i="19870" txt_f="19874">19.4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57703" xml_f="57719" txt_i="19875" txt_f="19891">0.78 (0.71–0.86)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57752" xml_f="57768" txt_i="19892" txt_f="19908">0.85 (0.77–0.93)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57801" xml_f="57806" txt_i="19909" txt_f="19914">0.001</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57839" xml_f="57844" txt_i="19915" txt_f="19920">0.001</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57877" xml_f="57882" txt_i="19921" txt_f="19926">0.060</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="57915" xml_f="57920" txt_i="19927" txt_f="19932">0.996</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="57962" xml_f="57969" txt_i="19933" txt_f="19940">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58002" xml_f="58005" txt_i="19941" txt_f="19944">181</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58038" xml_f="58042" txt_i="19945" txt_f="19949">13.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58075" xml_f="58078" txt_i="19950" txt_f="19953">232</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58111" xml_f="58115" txt_i="19954" txt_f="19958">17.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58148" xml_f="58151" txt_i="19959" txt_f="19962">271</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58184" xml_f="58188" txt_i="19963" txt_f="19967">20.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58221" xml_f="58237" txt_i="19968" txt_f="19984">0.63 (0.53–0.77)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58270" xml_f="58286" txt_i="19985" txt_f="20001">0.85 (0.71–1.01)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58319" xml_f="58324" txt_i="20002" txt_f="20007">0.001</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58357" xml_f="58362" txt_i="20008" txt_f="20013">0.067</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" colspan="1"><offsets xml_i="58470" xml_f="58484" txt_i="20016" txt_f="20030">Major bleeding</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58517" xml_f="58523" txt_i="20031" txt_f="20037">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58556" xml_f="58559" txt_i="20038" txt_f="20041">108</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58592" xml_f="58595" txt_i="20042" txt_f="20045">2.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58628" xml_f="58631" txt_i="20046" txt_f="20049">137</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58664" xml_f="58667" txt_i="20050" txt_f="20053">2.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58700" xml_f="58703" txt_i="20054" txt_f="20057">159</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58736" xml_f="58739" txt_i="20058" txt_f="20061">3.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58772" xml_f="58788" txt_i="20062" txt_f="20078">0.68 (0.53–0.87)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58821" xml_f="58837" txt_i="20079" txt_f="20095">0.89 (0.71–1.12)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58870" xml_f="58875" txt_i="20096" txt_f="20101">0.002</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58908" xml_f="58913" txt_i="20102" txt_f="20107">0.307</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58946" xml_f="58951" txt_i="20108" txt_f="20113">0.235</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="58984" xml_f="58989" txt_i="20114" txt_f="20119">0.888</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="59031" xml_f="59038" txt_i="20120" txt_f="20127">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59071" xml_f="59073" txt_i="20128" txt_f="20130">50</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59106" xml_f="59109" txt_i="20131" txt_f="20134">3.8</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59142" xml_f="59144" txt_i="20135" txt_f="20137">51</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59177" xml_f="59180" txt_i="20138" txt_f="20141">3.9</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59213" xml_f="59215" txt_i="20142" txt_f="20144">57</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59248" xml_f="59251" txt_i="20145" txt_f="20148">4.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59284" xml_f="59300" txt_i="20149" txt_f="20165">0.89 (0.61–1.30)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59333" xml_f="59349" txt_i="20166" txt_f="20182">0.92 (0.63–1.34)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59382" xml_f="59387" txt_i="20183" txt_f="20188">0.553</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59420" xml_f="59425" txt_i="20189" txt_f="20194">0.669</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="2" colspan="1"><offsets xml_i="59533" xml_f="59554" txt_i="20197" txt_f="20218">Intracranial bleeding</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59587" xml_f="59593" txt_i="20219" txt_f="20225">Absent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59626" xml_f="59627" txt_i="20226" txt_f="20227">7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59660" xml_f="59664" txt_i="20228" txt_f="20232">0.15</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59697" xml_f="59699" txt_i="20233" txt_f="20235">14</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59732" xml_f="59735" txt_i="20236" txt_f="20239">0.3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59768" xml_f="59770" txt_i="20240" txt_f="20242">34</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59803" xml_f="59806" txt_i="20243" txt_f="20246">0.7</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59839" xml_f="59855" txt_i="20247" txt_f="20263">0.21 (0.09–0.46)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59888" xml_f="59904" txt_i="20264" txt_f="20280">0.42 (0.23–0.79)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59937" xml_f="59942" txt_i="20281" txt_f="20286">0.001</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="59975" xml_f="59980" txt_i="20287" txt_f="20292">0.007</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="60013" xml_f="60018" txt_i="20293" txt_f="20298">0.764</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="60051" xml_f="60056" txt_i="20299" txt_f="20304">0.976</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="60098" xml_f="60105" txt_i="20305" txt_f="20312">Present</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="60138" xml_f="60139" txt_i="20313" txt_f="20314">4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="60172" xml_f="60176" txt_i="20315" txt_f="20319">0.31</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="60209" xml_f="60210" txt_i="20320" txt_f="20321">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="60243" xml_f="60246" txt_i="20322" txt_f="20325">0.0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="60279" xml_f="60281" txt_i="20326" txt_f="20328">16</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="60314" xml_f="60317" txt_i="20329" txt_f="20332">1.2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="60350" xml_f="60366" txt_i="20333" txt_f="20349">0.26 (0.09–0.77)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="60399" xml_f="60400" txt_i="20350" txt_f="20351">−</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="60433" xml_f="60438" txt_i="20352" txt_f="20357">0.015</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="60471" xml_f="60472" txt_i="20358" txt_f="20359">−</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="tblfn11"><p><offsets xml_i="60634" xml_f="60669" txt_i="20363" txt_f="20398">LVH, left ventricular hypertrophy; </offsets><italic><offsets xml_i="60677" xml_f="60678" txt_i="20398" txt_f="20399">N</offsets></italic><offsets xml_i="60687" xml_f="60758" txt_i="20399" txt_f="20470">, number of patients; yr, year; D, dabigatran; CI, confidence interval.</offsets></p></fn></table-wrap-foot></table-wrap></p></sec><sec><title><offsets xml_i="60820" xml_f="60872" txt_i="20473" txt_f="20525">International normalized ratio in the warfarin group</offsets></title><p><offsets xml_i="60883" xml_f="61150" txt_i="20526" txt_f="20793">Information on INR in the warfarin group was available in 3305 patients (97%) and missing in 118. The mean TTR in the warfarin group was 64.6%. The proportion of patients with TTR below the mean was higher in the presence than in the absence of LVH (48.8% vs. 41.8%; </offsets><italic><offsets xml_i="61158" xml_f="61159" txt_i="20793" txt_f="20794">P</offsets></italic><offsets xml_i="61168" xml_f="61275" txt_i="20794" txt_f="20898"> = 0.0008). To further explore this finding, we defined four groups on the basis of TTR: (i) TTR &gt; 80% (</offsets><italic><offsets xml_i="61283" xml_f="61284" txt_i="20898" txt_f="20899">n</offsets></italic><offsets xml_i="61293" xml_f="61324" txt_i="20899" txt_f="20930"> = 734; 22%); (ii) TTR 65–80% (</offsets><italic><offsets xml_i="61332" xml_f="61333" txt_i="20930" txt_f="20931">n</offsets></italic><offsets xml_i="61342" xml_f="61421" txt_i="20931" txt_f="21010"> = 1111; 34%); (iii) TTR ≤ 65%, but predominantly above the therapeutic range (</offsets><italic><offsets xml_i="61429" xml_f="61430" txt_i="21010" txt_f="21011">n</offsets></italic><offsets xml_i="61439" xml_f="61515" txt_i="21011" txt_f="21087"> = 423; 13%); (iv) TTR ≤ 65% but predominantly below the therapeutic range (</offsets><italic><offsets xml_i="61523" xml_f="61524" txt_i="21087" txt_f="21088">n</offsets></italic><offsets xml_i="61533" xml_f="61560" txt_i="21088" txt_f="21115"> = 1037; 31%). As shown in </offsets><italic><offsets xml_i="61568" xml_f="61575" txt_i="21115" txt_f="21122">Figure </offsets></italic><xref ref-type="fig" rid="eux022-F4"><italic><offsets xml_i="61629" xml_f="61630" txt_i="21122" txt_f="21123">4</offsets></italic></xref><offsets xml_i="61646" xml_f="61739" txt_i="21123" txt_f="21216">, LVH was associated with a poorer INR control, as reflected by the significant interaction (</offsets><italic><offsets xml_i="61747" xml_f="61748" txt_i="21216" txt_f="21217">P</offsets></italic><offsets xml_i="61757" xml_f="61816" txt_i="21217" txt_f="21276"> = 0.001) between TTR and LVH status in the warfarin group.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="61866" xml_f="61876" txt_i="21279" txt_f="21289">Discussion</offsets></title><p><offsets xml_i="61887" xml_f="61899" txt_i="21290" txt_f="21302">The present </offsets><italic><offsets xml_i="61907" xml_f="61915" txt_i="21302" txt_f="21310">post-hoc</offsets></italic><offsets xml_i="61924" xml_f="62700" txt_i="21310" txt_f="22086"> analysis of the RE-LY study showed two main findings. First, the primary RE-LY outcome (stroke and systemic embolism) was two-fold more frequent in the patients with than in those without LVH in the warfarin group. Conversely, the excess risk associated with LVH was smaller or negligible in the two dabigatran groups. Second, LVH was associated with a poorer INR control in the warfarin group. Consequently, the lower dose of dabigatran was superior to warfarin in reducing the primary RE-LY outcome in patients with LVH, while the higher dose of dabigatran remained superior to warfarin regardless of LVH. The interaction of LVH status with the effects of dabigatran 110 mg vs. warfarin was thus largely explained by the poorer performance of warfarin in patients with LVH.</offsets></p><p><offsets xml_i="62707" xml_f="62849" txt_i="22087" txt_f="22229">We defined LVH by traditional ECG using a validated score (‘Perugia score’) which improved cardiovascular risk stratification in patients with</offsets><xref rid="eux022-B1" ref-type="bibr"><sup><offsets xml_i="62892" xml_f="62893" txt_i="22229" txt_f="22230">1</offsets></sup></xref><offsets xml_i="62906" xml_f="62918" txt_i="22230" txt_f="22242"> and without</offsets><xref rid="eux022-B20" ref-type="bibr"><sup><offsets xml_i="62962" xml_f="62964" txt_i="22242" txt_f="22244">20</offsets></sup></xref><offsets xml_i="62977" xml_f="63218" txt_i="22244" txt_f="22485"> AF. The added prognostic value of ECG-LVH in patients with evidence of AF on the ECG at entry is supported by a prior analysis of RE-LY, in which ECG-LVH improved risk stratification and discrimination in AF patients over and beyond the CHA</offsets><sub><offsets xml_i="63223" xml_f="63224" txt_i="22485" txt_f="22486">2</offsets></sub><offsets xml_i="63230" xml_f="63232" txt_i="22486" txt_f="22488">DS</offsets><sub><offsets xml_i="63237" xml_f="63238" txt_i="22488" txt_f="22489">2</offsets></sub><offsets xml_i="63244" xml_f="63278" txt_i="22489" txt_f="22523">VASc score and other risk markers.</offsets><xref rid="eux022-B1" ref-type="bibr"><sup><offsets xml_i="63321" xml_f="63322" txt_i="22523" txt_f="22524">1</offsets></sup></xref></p><p><xref rid="eux022-B21" ref-type="bibr"><sup><offsets xml_i="63386" xml_f="63388" txt_i="22525" txt_f="22527">21</offsets></sup></xref><offsets xml_i="63401" xml_f="63407" txt_i="22527" txt_f="22533"> In a </offsets><italic><offsets xml_i="63415" xml_f="63423" txt_i="22533" txt_f="22541">post-hoc</offsets></italic><offsets xml_i="63432" xml_f="63566" txt_i="22541" txt_f="22675"> analysis of the RE-LY study, the relative benefits of dabigatran vs. warfarin were similar in patients with and without hypertension.</offsets><xref rid="eux022-B22" ref-type="bibr"><sup><offsets xml_i="63610" xml_f="63612" txt_i="22675" txt_f="22677">22</offsets></sup></xref><offsets xml_i="63625" xml_f="63818" txt_i="22677" txt_f="22870"> However, the relative benefit of dabigatran 110 mg vs. warfarin on the risk of the primary RE-LY outcome bordered statistical significance in hypertensive patients (HR 0.81; 95% CI 0.65–1.02; </offsets><italic><offsets xml_i="63826" xml_f="63827" txt_i="22870" txt_f="22871">P</offsets></italic><offsets xml_i="63836" xml_f="63989" txt_i="22871" txt_f="23024"> for interaction = 0.0547), while the benefit of dabigatran 150 mg vs. warfarin was statistically significant in patients with and without hypertension (</offsets><italic><offsets xml_i="63997" xml_f="63998" txt_i="23024" txt_f="23025">P</offsets></italic><offsets xml_i="64007" xml_f="64034" txt_i="23025" txt_f="23052"> for interaction = 0.6207).</offsets><xref rid="eux022-B22" ref-type="bibr"><sup><offsets xml_i="64078" xml_f="64080" txt_i="23052" txt_f="23054">22</offsets></sup></xref></p><p><offsets xml_i="64100" xml_f="64323" txt_i="23055" txt_f="23278">Less clear is the direct relation between LVH and coagulation. Lip and co-workers first showed increased levels of fibrinogen, and an association between fibrinogen and left ventricular mass (LVM), in hypertensive patients.</offsets><xref rid="eux022-B3" ref-type="bibr"><sup><offsets xml_i="64366" xml_f="64367" txt_i="23278" txt_f="23279">3</offsets></sup></xref><offsets xml_i="64380" xml_f="64684" txt_i="23279" txt_f="23583"> Other reports confirmed a link between LVH and enhanced coagulation. In a study of 230 anticoagulated patients who underwent transoesophageal echocardiography (TEE) prior to cardioversion or catheter ablation of AF, LVH and persistent AF were the only two independent predictors of left atrial thrombus.</offsets><xref rid="eux022-B2" ref-type="bibr"><sup><offsets xml_i="64727" xml_f="64728" txt_i="23583" txt_f="23584">2</offsets></sup></xref><offsets xml_i="64741" xml_f="64920" txt_i="23584" txt_f="23763"> In another study of 123 anticoagulated patients with AF who underwent TEE, left atrial thrombi were noted in 33% of patients with LVH, as opposed to 13% of patients without LVH (</offsets><italic><offsets xml_i="64928" xml_f="64929" txt_i="23763" txt_f="23764">P</offsets></italic><offsets xml_i="64938" xml_f="64951" txt_i="23764" txt_f="23774"> &lt; 0.001).</offsets><xref rid="eux022-B7" ref-type="bibr"><sup><offsets xml_i="64994" xml_f="64995" txt_i="23774" txt_f="23775">7</offsets></sup></xref><offsets xml_i="65008" xml_f="65141" txt_i="23775" txt_f="23908"> In a study of 129 anticoagulated patients with AF who underwent TEE, LVM was the only parameter predictive of left atrial thrombus (</offsets><italic><offsets xml_i="65149" xml_f="65150" txt_i="23908" txt_f="23909">P</offsets></italic><offsets xml_i="65159" xml_f="65205" txt_i="23909" txt_f="23952"> &lt; 0.001) in a multivariate logistic model.</offsets><xref rid="eux022-B6" ref-type="bibr"><sup><offsets xml_i="65248" xml_f="65249" txt_i="23952" txt_f="23953">6</offsets></sup></xref></p><p><offsets xml_i="65269" xml_f="65571" txt_i="23954" txt_f="24256">It remains unclear why the adverse prognostic impact of LVH in the present study was greater in the warfarin group than in the two dabigatran groups. In the warfarin group, patients with LVH showed a poorer control of INR than those without LVH, thereby justifying their higher risk of thromboembolism.</offsets><xref rid="eux022-B23" ref-type="bibr"><sup><offsets xml_i="65615" xml_f="65617" txt_i="24256" txt_f="24258">23</offsets></sup></xref><offsets xml_i="65630" xml_f="65803" txt_i="24258" txt_f="24431"> In a study conducted in 2223 anticoagulated patients with non-valvular AF, for any 10% increase in the time with INR out of range there was a 29% higher risk of mortality (</offsets><italic><offsets xml_i="65811" xml_f="65812" txt_i="24431" txt_f="24432">P</offsets></italic><offsets xml_i="65821" xml_f="65874" txt_i="24432" txt_f="24482"> &lt; 0.001), a 10% higher risk of ischaemic stroke (</offsets><italic><offsets xml_i="65882" xml_f="65883" txt_i="24482" txt_f="24483">P</offsets></italic><offsets xml_i="65892" xml_f="65955" txt_i="24483" txt_f="24546"> = 0.006) and a 12% higher risk of other thromboembolic events.</offsets><xref rid="eux022-B24" ref-type="bibr"><sup><offsets xml_i="65999" xml_f="66001" txt_i="24546" txt_f="24548">24</offsets></sup></xref></p><p><offsets xml_i="66021" xml_f="66340" txt_i="24549" txt_f="24868">To the best of our knowledge, this is the first study to show that LVH is associated with a moderately poorer control of INR in patients with non-valvular AF receiving warfarin. LVH might be a marker for a poor adherence not only to antihypertensive treatment, as reflected by the higher BP values associated with LVH (</offsets><italic><offsets xml_i="66348" xml_f="66354" txt_i="24868" txt_f="24874">Table </offsets></italic><xref ref-type="table" rid="eux022-T1"><italic><offsets xml_i="66410" xml_f="66411" txt_i="24874" txt_f="24875">1</offsets></italic></xref><offsets xml_i="66427" xml_f="66804" txt_i="24875" txt_f="25252">), but also to warfarin, as reflected by the lower TTR. However, the poorer control of INR appears to be unable to fully explain the two-fold higher risk of the primary outcome and stroke in the LVH group. The design of the present study does not allow us to clarify the pathological mechanisms of this phenomenon. LVH may be associated with overt or subclinical heart failure.</offsets><xref rid="eux022-B25" ref-type="bibr"><sup><offsets xml_i="66848" xml_f="66850" txt_i="25252" txt_f="25254">25</offsets></sup></xref><offsets xml_i="66863" xml_f="67113" txt_i="25254" txt_f="25504"> The decrease in oxygen delivery to the liver, potentially associated with episodes of heart failure, might impair the hepatic clearance of warfarin via cytochrome P450, known to require a considerable amount of oxygen to perform oxidative reactions.</offsets><xref rid="eux022-B26" ref-type="bibr"><sup><offsets xml_i="67157" xml_f="67159" txt_i="25504" txt_f="25506">26</offsets></sup></xref><offsets xml_i="67172" xml_f="67357" txt_i="25506" txt_f="25691"> This intriguing hypothesis is supported by the evidence that patients admitted to hospital for exacerbations of heart failure show INR instability and enhanced sensitivity to warfarin.</offsets><xref rid="eux022-B27" ref-type="bibr"><sup><offsets xml_i="67401" xml_f="67403" txt_i="25691" txt_f="25693">27</offsets></sup></xref><offsets xml_i="67416" xml_f="67846" txt_i="25693" txt_f="26123"> An enhanced sensitivity to warfarin in the acute phase of heart failure might lead to difficulties in the management of INR even in the long term. In contrast, the elimination of dabigatran, which is predominantly renal, would be less affected by episodes of heart failure associated with LVH. Consequently, the antithrombotic potential of dabigatran could be less impaired by LVH when compared with warfarin. We included the CHA</offsets><sub><offsets xml_i="67851" xml_f="67852" txt_i="26123" txt_f="26124">2</offsets></sub><offsets xml_i="67858" xml_f="67860" txt_i="26124" txt_f="26126">DS</offsets><sub><offsets xml_i="67865" xml_f="67866" txt_i="26126" txt_f="26127">2</offsets></sub><offsets xml_i="67872" xml_f="68090" txt_i="26127" txt_f="26345">VASc score, which encompasses congestive heart failure, in the multivariate model comparing the treatments and testing their interaction with LVH status. Our results did not change when the single components of the CHA</offsets><sub><offsets xml_i="68095" xml_f="68096" txt_i="26345" txt_f="26346">2</offsets></sub><offsets xml_i="68102" xml_f="68104" txt_i="26346" txt_f="26348">DS</offsets><sub><offsets xml_i="68109" xml_f="68110" txt_i="26348" txt_f="26349">2</offsets></sub><offsets xml_i="68116" xml_f="68170" txt_i="26349" txt_f="26403">VASc score were forced into the multivariate analysis.</offsets></p><p><offsets xml_i="68177" xml_f="68304" txt_i="26404" txt_f="26531">LVH may be associated not only with disorders of coagulation, but also with a state of chronic low-grade systemic inflammation.</offsets><xref rid="eux022-B4" ref-type="bibr"><sup><offsets xml_i="68347" xml_f="68348" txt_i="26531" txt_f="26532">4</offsets></sup></xref><sup><offsets xml_i="68366" xml_f="68367" txt_i="26532" txt_f="26533">,</offsets></sup><xref rid="eux022-B5" ref-type="bibr"><sup><offsets xml_i="68416" xml_f="68417" txt_i="26533" txt_f="26534">5</offsets></sup></xref><offsets xml_i="68430" xml_f="68500" txt_i="26534" txt_f="26604"> Thrombin participates in the mechanisms of inflammation and fibrosis.</offsets><xref rid="eux022-B8" ref-type="bibr"><sup><offsets xml_i="68543" xml_f="68547" txt_i="26604" txt_f="26608">8–10</offsets></sup></xref><offsets xml_i="68560" xml_f="68700" txt_i="26608" txt_f="26748"> There is experimental evidence that inflammatory and fibrotic reactions may be counteracted by selective thrombin blockade with dabigatran.</offsets><xref rid="eux022-B11" ref-type="bibr"><sup><offsets xml_i="68744" xml_f="68746" txt_i="26748" txt_f="26750">11</offsets></sup></xref><sup><offsets xml_i="68764" xml_f="68765" txt_i="26750" txt_f="26751">,</offsets></sup><xref rid="eux022-B12" ref-type="bibr"><sup><offsets xml_i="68815" xml_f="68817" txt_i="26751" txt_f="26753">12</offsets></sup></xref><offsets xml_i="68830" xml_f="68979" txt_i="26753" txt_f="26902"> Studies in humans are needed to clarify whether selective thrombin blockade offers an advantage over warfarin in a context of systemic inflammation.</offsets></p><sec><title><offsets xml_i="68995" xml_f="69019" txt_i="26903" txt_f="26927">Limitations of the study</offsets></title><p><offsets xml_i="69030" xml_f="69070" txt_i="26928" txt_f="26968">Firstly, stemming from an unanticipated </offsets><italic><offsets xml_i="69078" xml_f="69086" txt_i="26968" txt_f="26976">post-hoc</offsets></italic><offsets xml_i="69095" xml_f="70521" txt_i="26976" txt_f="28402"> analysis, our findings should not be viewed as definitive, but rather as hypothesis-generating and subjected to the play of chance. Secondly, our study lacks imaging assessment of LVH, which could have resulted in better precision. An echocardiographic study was not systematically performed in the RE-LY trial. To the best of our knowledge, none of the other mega-trials with oral non vitamin K antagonists vs. warfarin have sufficient echocardiographic information to test the link between baseline LVM and outcome. Such association should be addressed in future studies. Thirdly, our investigation has been specifically conducted in the RE-LY patients with ECG evidence of AF at entry, not in the entire RE-LY population. We pre-specified this aspect in order to make results applicable to patients with actual evidence of AF on the index ECG, regardless of the type of AF (paroxysmal, persistent or permanent), because the prognostic value of LVH in patients with sinus rhythm on the ECG tracings is well established. Finally, the difference in TTR between the patients with and without LVH in the warfarin group was numerically small, albeit statistically significant. The strength of this study was that all ECG tracings were examined by a single experienced reader in blind conditions with regard to clinical features and randomized treatment. Because of the high number of ECG tracings which required manual reading (</offsets><italic><offsets xml_i="70529" xml_f="70530" txt_i="28402" txt_f="28403">n</offsets></italic><offsets xml_i="70539" xml_f="70643" txt_i="28403" txt_f="28507"> = 13 047), we could not rely on a higher number of readers for assessment of interpersonal variability.</offsets></p></sec><sec><title><offsets xml_i="70665" xml_f="70676" txt_i="28509" txt_f="28520">Conclusions</offsets></title><p><offsets xml_i="70687" xml_f="71099" txt_i="28521" txt_f="28933">In conclusion, this study suggests that LVH on ECG portends a reduced antithrombotic efficacy of warfarin, but not dabigatran, in patients with ECG evidence of AF. Consequently, the lower dose of dabigatran (110 mg) was better than warfarin in reducing the risk of primary RE-LY outcome and stroke in AF patients with LVH. The higher dose of dabigatran (150 mg) was superior to warfarin regardless of LVH status.</offsets></p><p><offsets xml_i="71106" xml_f="71107" txt_i="28934" txt_f="28935">
</offsets><bold><offsets xml_i="71113" xml_f="71134" txt_i="28935" txt_f="28956">Conflict of interest:</offsets></bold><offsets xml_i="71141" xml_f="72573" txt_i="28956" txt_f="30376"> Dr Verdecchia and Dr Di Pasquale received research grants, consulting fees, and lecture fees from Boehringer Ingelheim. Dr Connolly has received consulting and research grants from Boehringer Ingelheim. Dr Ezekowitz is a consultant for and/or has received consulting/honoraria fees from Boehringer Ingelheim, Pfizer, Sanofi, Bristol-Myers Squibb, Portola, Bayer, Daiichi-Sankyo, Medtronic, Aegerion, Merck, Johnson &amp; Johnson, Gilead, Janssen Scientific Affairs, Pozen Inc., Amgen, Coherex, and Armetheon. Dr Yusuf has received research grants from Boehringer Ingelheim. Dr Wallentin has received research grants, consultancy and lecture fees, honoraria, and travel support from AstraZeneca, Bristol-Myers Squibb/Pfizer, and GlaxoSmithKline; research grants, consultancy and lecture fees, and honoraria from Boehringer Ingelheim; research grants and consultancy fees from Merck &amp; Co.; and consultancy fees from Abbott, Athera Biotechnologies, and Regado Biosciences. Dr Lip is a consultant for Bayer/Janssen, Astellas, Merck, Sanofi, Bristol-Myers Squibb/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife and Daiichi-Sankyo. Dr Lip is a speaker for Bayer, Bristol-Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. Eva Kleine and Martina Brueckmann are full-time employees of Boehringer Ingelheim GmbH &amp; Co. KG, Germany. The other authors report no conflicts.</offsets></p></sec></sec><sec><title><offsets xml_i="72601" xml_f="72608" txt_i="30379" txt_f="30386">Funding</offsets></title><p><offsets xml_i="72619" xml_f="72712" txt_i="30387" txt_f="30480">The RE-LY study was funded by Boehringer Ingelheim, Germany. This analysis was funded by the </offsets><italic><offsets xml_i="72720" xml_f="72757" txt_i="30480" txt_f="30517">Fondazione Umbra Cuore e Ipertensione</offsets></italic><offsets xml_i="72766" xml_f="72791" txt_i="30517" txt_f="30542"> – ONLUS, Perugia, Italy.</offsets></p></sec></body><back><ref-list><title>References</title><ref id="eux022-B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Verdecchia</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Reboldi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Di Pasquale</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mazzotta</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ambrosio</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>S</given-names></name></person-group>
<etal></etal>
<article-title>Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study)</article-title>. <source>Am J Cardiol</source><year>2014</year>;<volume>113</volume>:<fpage>669</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">24359765</pub-id></mixed-citation></ref><ref id="eux022-B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kishima</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Mine</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kodani</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Masuyama</surname><given-names>T.</given-names></name></person-group>
<article-title>Prediction of left atrial thrombi in patients with atrial tachyarrhythmias during warfarin administration: retrospective study in Hyogo College of Medicine</article-title>. <source>Heart Vessels</source><year>2015</year>;<volume>30</volume>:<fpage>331</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">24658886</pub-id></mixed-citation></ref><ref id="eux022-B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lip</surname><given-names>GY</given-names></name>, <name name-style="western"><surname>Blann</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>AF</given-names></name>, <name name-style="western"><surname>Lip</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Beevers</surname><given-names>DG.</given-names></name></person-group>
<article-title>Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy</article-title>. <source>Am J Cardiol</source><year>1997</year>;<volume>80</volume>:<fpage>1566</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">9416937</pub-id></mixed-citation></ref><ref id="eux022-B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Moriguchi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yogo</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Aizawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Serizawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tashiro</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yorozu</surname><given-names>K</given-names></name></person-group>
<etal></etal>
<article-title>Left ventricular hypertrophy is associated with inflammation in sodium loaded subtotal nephrectomized rats</article-title>. <source>Biomed Res</source><year>2011</year>;<volume>32</volume>:<fpage>83</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">21551943</pub-id></mixed-citation></ref><ref id="eux022-B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Salles</surname><given-names>GF</given-names></name>, <name name-style="western"><surname>Fiszman</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cardoso</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Muxfeldt</surname><given-names>ES.</given-names></name></person-group>
<article-title>Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension</article-title>. <source>Hypertension</source><year>2007</year>;<volume>50</volume>:<fpage>723</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">17635853</pub-id></mixed-citation></ref><ref id="eux022-B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Boyd</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>McKay</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nasibi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Richards</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>L.</given-names></name></person-group>
<article-title>Left ventricular mass predicts left atrial appendage thrombus in persistent atrial fibrillation</article-title>. <source>Eur Heart J Cardiovasc Imaging</source><year>2013</year>;<volume>14</volume>:<fpage>269</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">22833549</pub-id></mixed-citation></ref><ref id="eux022-B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wasaki</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ogawa</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Nakatsuka</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wakeyama</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Iwami</surname><given-names>T</given-names></name></person-group>
<etal></etal>
<article-title>Effect of low-intensity warfarin therapy on left atrial thrombus resolution in patients with nonvalvular atrial fibrillation: a transesophageal echocardiographic study</article-title>. <source>Jpn Circ J</source><year>2001</year>;<volume>65</volume>:<fpage>271</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">11316121</pub-id></mixed-citation></ref><ref id="eux022-B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Rondeau</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Coughlin</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Holdsworth</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Tipping</surname><given-names>PG.</given-names></name></person-group>
<article-title>Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis</article-title>. <source>J Exp Med</source><year>2000</year>;<volume>191</volume>:<fpage>455</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">10662791</pub-id></mixed-citation></ref><ref id="eux022-B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nelken</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Soifer</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>O'Keefe</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vu</surname><given-names>TK</given-names></name>, <name name-style="western"><surname>Charo</surname><given-names>IF</given-names></name>, <name name-style="western"><surname>Coughlin</surname><given-names>SR.</given-names></name></person-group>
<article-title>Thrombin receptor expression in normal and atherosclerotic human arteries</article-title>. <source>J Clin Invest</source><year>1992</year>;<volume>90</volume>:<fpage>1614</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">1328304</pub-id></mixed-citation></ref><ref id="eux022-B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Spronk</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>de Jong</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Crijns</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Schotten</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Van Gelder</surname><given-names>IC</given-names></name>, <name name-style="western"><surname>Ten Cate</surname><given-names>H.</given-names></name></person-group>
<article-title>Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants</article-title>. <source>Cardiovasc Res</source><year>2014</year>;<volume>101</volume>:<fpage>344</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">24385341</pub-id></mixed-citation></ref><ref id="eux022-B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bogatkevich</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Ludwicka-Bradley</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nietert</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Akter</surname><given-names>T</given-names></name>, <name name-style="western"><surname>van Ryn</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Silver</surname><given-names>RM.</given-names></name></person-group>
<article-title>Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease</article-title>. <source>Arthritis Rheum</source><year>2011</year>;<volume>63</volume>:<fpage>1416</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">21312187</pub-id></mixed-citation></ref><ref id="eux022-B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Borissoff</surname><given-names>JI</given-names></name>, <name name-style="western"><surname>Otten</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Heeneman</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Leenders</surname><given-names>P</given-names></name>, <name name-style="western"><surname>van Oerle</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Soehnlein</surname><given-names>O</given-names></name></person-group>
<etal></etal>
<article-title>Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner</article-title>. <source>PLoS One</source><year>2013</year>;<volume>8</volume>:<fpage>e55784</fpage>.<pub-id pub-id-type="pmid">23409043</pub-id></mixed-citation></ref><ref id="eux022-B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Connolly</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Ezekowitz</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Yusuf</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Eikelboom</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Oldgren</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Parekh</surname><given-names>A</given-names></name></person-group>
<etal></etal>
<article-title>Dabigatran versus warfarin in patients with atrial fibrillation</article-title>. <source>N Engl J Med</source><year>2009</year>;<volume>361</volume>:<fpage>1139</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">19717844</pub-id></mixed-citation></ref><ref id="eux022-B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ezekowitz</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Connolly</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Parekh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Reilly</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Varrone</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S</given-names></name></person-group>
<etal></etal>
<article-title>Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran</article-title>. <source>Am Heart J</source><year>2009</year>;<volume>157</volume>:<fpage>805</fpage>–<lpage>10</lpage>, 810 e801-802.<pub-id pub-id-type="pmid">19376304</pub-id></mixed-citation></ref><ref id="eux022-B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Verdecchia</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Reboldi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Carluccio</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Benemio</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gattobigio</surname><given-names>R</given-names></name></person-group>
<etal></etal>
<article-title>Improved cardiovascular risk stratification by a simple ECG index in hypertension</article-title>. <source>Am J Hypertens</source><year>2003</year>;<volume>16</volume>:<fpage>646</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">12878370</pub-id></mixed-citation></ref><ref id="eux022-B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kannel</surname><given-names>WB</given-names></name>, <name name-style="western"><surname>Gordon</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Offutt</surname><given-names>D.</given-names></name></person-group>
<article-title>Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study</article-title>. <source>Ann Intern Med</source><year>1969</year>;<volume>71</volume>:<fpage>89</fpage>–<lpage>105</lpage>.<pub-id pub-id-type="pmid">4239887</pub-id></mixed-citation></ref><ref id="eux022-B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Verdecchia</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Porcellati</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Reboldi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gattobigio</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Borgioni</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pearson</surname><given-names>TA</given-names></name></person-group>
<etal></etal>
<article-title>Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension</article-title>. <source>Circulation</source><year>2001</year>;<volume>104</volume>:<fpage>2039</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">11673343</pub-id></mixed-citation></ref><ref id="eux022-B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>DR.</given-names></name></person-group>
<article-title>Regression models and lifetables</article-title>. <source>J R Stat Soc [B]</source><year>1972</year>;<volume>34</volume>:<fpage>187</fpage>–<lpage>220</lpage>.</mixed-citation></ref><ref id="eux022-B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lip</surname><given-names>GY</given-names></name>, <name name-style="western"><surname>Nieuwlaat</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Pisters</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lane</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Crijns</surname><given-names>HJ.</given-names></name></person-group>
<article-title>Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation</article-title>. <source>Chest</source><year>2010</year>;<volume>137</volume>:<fpage>263</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">19762550</pub-id></mixed-citation></ref><ref id="eux022-B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Verdecchia</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sleight</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mancia</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Fagard</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Trimarco</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Schmieder</surname><given-names>RE</given-names></name></person-group>
<etal></etal>
<article-title>Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease</article-title>. <source>Circulation</source><year>2009</year>;<volume>120</volume>:<fpage>1380</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">19770395</pub-id></mixed-citation></ref><ref id="eux022-B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Verdecchia</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Achilli</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Castellani</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Broccatelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gattobigio</surname><given-names>R</given-names></name></person-group>
<etal></etal>
<article-title>Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events?</article-title>
<source>Curr Opin Cardiol</source>
<year>2007</year>;<volume>22</volume>:<fpage>329</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">17556886</pub-id></mixed-citation></ref><ref id="eux022-B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nagarakanti</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wallentin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Noack</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Brueckmann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Reilly</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Clemens</surname><given-names>A</given-names></name></person-group>
<etal></etal>
<article-title>Comparison of characteristics and outcomes of Dabigatran versus Warfarin in hypertensive patients with atrial fibrillation (from the RE-LY Trial)</article-title>. <source>Am J Cardiol</source><year>2015</year>;<volume>116</volume>:<fpage>1204</fpage>–<lpage>09</lpage>.<pub-id pub-id-type="pmid">26282726</pub-id></mixed-citation></ref><ref id="eux022-B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hylek</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Skates</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Sheehan</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Singer</surname><given-names>DE.</given-names></name></person-group>
<article-title>An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation</article-title>. <source>N Engl J Med</source><year>1996</year>;<volume>335</volume>:<fpage>540</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">8678931</pub-id></mixed-citation></ref><ref id="eux022-B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>M</given-names></name>, <name name-style="western"><surname>McEwan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Morgan</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Goodfellow</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Currie</surname><given-names>CJ.</given-names></name></person-group>
<article-title></article-title>. <source>Heart</source><year>2005</year>;<volume>91</volume>:<fpage>472</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">15772203</pub-id></mixed-citation></ref><ref id="eux022-B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Larson</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Vasan</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Kannel</surname><given-names>WB</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>KK.</given-names></name></person-group>
<article-title>The progression from hypertension to congestive heart failure</article-title>. <source>JAMA</source><year>1996</year>;<volume>275</volume>:<fpage>1557</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">8622246</pub-id></mixed-citation></ref><ref id="eux022-B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>DP.</given-names></name></person-group>
<article-title>Hypoxia and drug metabolism</article-title>. <source>Biochem Pharmacol</source><year>1981</year>;<volume>30</volume>:<fpage>1019</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">7259789</pub-id></mixed-citation></ref><ref id="eux022-B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>del Campo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>G.</given-names></name></person-group>
<article-title>Changes in Warfarin sensitivity during decompensated heart failure and chronic obstructive pulmonary disease</article-title>. <source>Ann Pharmacother</source><year>2015</year>;<volume>49</volume>:<fpage>962</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">26104049</pub-id></mixed-citation></ref></ref-list></back></article>